3101. Sultan, S., Chouinard, G., and Beaudry, P., Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis, Prog. Neuropsychopharmacol. Biol. Psychiatry, 14: 431-38, 1990.

3102. McNamara, M.E. and Fogel, B.S., Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities, J. Neuropsych., 2(2): 193-196, 1990.

3103. Fan, Z., Zhang, Z., Lu, G., and Huang, Z., The effect of phenytoin treated depressive psychosis, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3104. Yao, D., Zhang, X., and Wang, B., Administration of phenytoin to treat the mental symptoms of Alzheimer's patients, Arch. Psychiatr. (Shanghai Psychiatry), 5(1): 38-40, 1993.

3105. Liu, D., Wei, M., Liu, Y., Ling, J., Lu, Q., and Wang, J.T., A double-blind study of the effect of phenytoin on anxiety and neurotic depressions, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3106. Mishory, A.,Yaroslavsky, Y., Bersudsky, Y., and Belmaker, R.H., Phenytoin as an antimanic anticonvulsant: a controlled study, Am. J. Psychiatry, 157(3): 463-465, 2000.

3107. Brown, E.S., Stuard, G., Liggin, J.D.M., Hukovic, N., Frol, A., Dhanani, N., Khan, D.A., Jeffress, J., Larkin, G.L., McEwen, B.S., et. al., Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy, Biol. Psychiatry, 57:543-548, 2005.

3108. Medvedev, S.V., Grachetva, G.M., Belov, M.A., and Stetsenko, O.V., The influence of dilantin on the course of psychic processes in humans, Personal Communication, 1992.

3109. Huang, M. and Ling, X., A controlled study of the effects of phenytoin on anxiety, West China Med. J., 7(4): 407-408, 1992.

3110. Greist, J.H., Current use of carbamazepine and other anticonvulsants as lithium alternatives in bipolar disorders, Int. Clin. Psychopharmacol., 5: 15-26, 1990.

3111. Keck, P.E. and McElroy, S.L., Anticonvulsants in the treatment of rapid-cycling bipolar disorder, Use of Anticonvulsants in Psychiatry: Recent Advances, 115-125, McElroy, S.L. and Pope, H.G., Eds., Oxford Health Care, Inc., Clifton, NJ, 1988.

3112. Post, R.M. and Ubde, T.W., Refractory manias and alternatives to lithium treatment, Depression and Mania, 410-438, Georgotas, A., et al, Eds., Elsevier, NY, 1988.

3113. Delucchi, G.A. and Calabrese, J.R., Anticonvulsants for treatment of manic depression, Cleve. Clin. J. Med., 56: 756-761, 1989.

3114. Zhang, Y., et al., The study of phenytoin in the treatment of obsessive-compulsive disorder with double-blind, placebo-controlled trial, China Med. Abstr.,11(2):68, 1994.

3115. Shan, Y., The effect of phenytoin on Gilles de la Tourette Syndrome, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3116. Barratt, E.S., Shappell, S.A., and Brandt, M.E., Effects of acute phenytoin on cortical event-related potentials, Soc. Neurosci. Abstr., 14(PT 2): 1105, 1988.

3117. Barratt, E.S., Kent, T., Bryant, S., Felthous, A., and Stanford, M., Phenytoin improves brain functions among impulsive aggressive prisoners, Soc. Neurosci. Abstr.,16(PT 1): 141, 1990.

3118. Barratt, E.S., Kent, T.A., Bryant, S.G., and Felthous, A.R., A controlled trial of phenytoin in impulsive aggression, J. Clin. Psychopharmacology, 11(6): 388-389, 1991.

3119. Barratt, E.S., Kent, T., and Stanford, M., The effects of phenytoin on event-related potentials among impulsive aggressive prisoners, Presented at the 3rd International Brain Research Organization World Congress of Neuroscience, Montreal, Canada, 342, ABS P53.10, 1991.

3120. Barratt, E.S. and Kent, T., The effects of phenytoin (PHT) on frontal and parietal event-related potentials(ERPs) among impulsive aggressive prisoners, Presented at the XVIIIth Collegium International Neuropsychopharmacolicum Congress, Nice, France, 1992.

3121. Zhou, J., The use of diphenylhydantoin in psychotic patients with aggressive behavior, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3122. Barratt, E.S., Stanford, M.S., Felthous, A.R., and Kent, T.A., The effects of phenytoin on impulsive and premeditated aggression: a controlled study, J. Clin. Psychopharmacology, 17(5): 341-349, 1997.

3123. Houston, R.J., Mathias, C.W., Johnston, M.S., Villemarette-Pittman, N., and Stanford, M.S., The effect of phenytoin on mid-latency evoked potentials in impulsive aggression, Psychophysiology, abs 37(S49), 2000.

3124. Stanford M.S., Helfritz, L.E., Conklin, S.M., Villemarette-Pittman, N.R., Greve, K.W., Adams, D., and Houston, R.J., A comparison of anticonvulsants in the treatment of impulsive aggression, Exp. Clin. Psychopharmacology, 13(1):72-77, 2005.

3125. Barratt, E.S., Felthous, A., Kent, T., Liebman, M.J., and Coates, D.D., Criterion measures of aggression - impulsive versus premeditated aggression, The Science, Treatment, and Prevention of Antisocial Behavior: Application to the Criminal Justice System, 41-4-18, Fishbein, D.H., Ed., Civic Research Institute, Kingston, NY, 2000.

3126. Barratt, E.S. and Slaughter, L., Defining, measuring, predicting impulsive aggression: a heuristic model, Behav. Sci. Law,16(3):285-302, 1998.

3127. Barratt, E.S., Stanford, M.S., Dowdy, L., Liebman, M.J., and Kent, T.A., Impulsive and premeditated aggression: A factor analysis of self-reported acts, Psychiatry Res., 86(2): 163-173, 1999.

3128. Barratt, E.S., Impulsiveness and aggression, Violence and Mental Disorder: Developments in Risk Assessment, 61-79, Monahan, J. and Steadman, H.J., Eds., University of Chicago, Chicago, IL, 1994.

3129. Johnson, G.F., Psychopharmacology of aggression, Limbic Epilepsy and the Dyscontrol Syndrome, Proceedings of the First International Symposium on Limbic Epilepsy and the Dyscontrol Syndrome, Sydney, Australia, 207-18, Girgis, M. and Kiloh, L.G., Eds., Elsevier/North-Holland Biomedical Press, Amsterdam, 1980

3130. Maletzky, B.M., Treatable violence, Med. Times, 100(10): 74-9, 1972.

3131. Barratt, E.S., The use of anticonvulsants in aggression and violence, Psychopharmacol. Bull., 29(1): 75-81, 1993.

3132. Laudadio, S., Crisci, M., De Carolis, P., Pezzoli, A., and Sacquegna, T., Acute psychosis and epileptic seizures as the presenting symptom of late-onset epilepsy, Acta. Neurol. Scand., 89(1):77-9, 1994.

3135. Craig, I. and Tallis, R., Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study, Epilepsia, 35(2): 381-90, 1994.

3136. Dodrill, C.B. and Troupin, A.S., Neuropsychological effects of carbamezepine and phenytoin: a reanalysis, Neurology, 41: 141-3, 1991.

3137. Huang, M., Li, J., and Shan, Y. Effect of phenytoin in hyperactive children, National Workshop of Clinical Use of Phenytoin, Chengdu, China (1992)

3138. Huang, M., Li, J., and Shan, Y., The effect of phenytoin on hyperactivity in children, Personal Communication, 1995.

3139. De Sousa, A., De Sousa, D.A., and Sinorawala, A.K., Diphenylhydantoin in alcohol withdrawal states, J. Commun. Psychiatry, 11: 19-21, 1988.

3140. De Sousa, A. and De Sousa, D.A., Diphenylhydantoin in heroin withdrawal, J. Commun. Psychiatry, 11: 3-4, 1988.

3141. Alldredge, B.K., Lowenstein, D.H., and Simon, R.P., Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures, Am. J. Med., 87: 645-48, 1989.

3142. Shah, B.S. and Ratner, H., Phenytoin and smoking, NY State J. Med., 92(2): 71-72,1992.

3143. Shah, B.S. and Ratner, H., Anti-convulsant drugs, smoking, and body weights in psychiatric in-patients, N.Y. State J. Med., 93(1): 16-17, 1993.

3144. Ilyuchina, V.A. and Nikitina, L.I., Clinical physiologic study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism, Alcohol, 12(6):511-17, 1995.

3145. Rao, A. and Suneetha, V.T., A controlled trial of phenytoin and chlordiazepoxide (Librium) during the acute alcohol withdrawal period, Personal Communication, 1-20, 1994.

3146. Crosby, R.D., Pearson, V.L., Eller, C., Winegarden, T., and Graves, N.L., Phenytoin in the treatment of cocaine abuse: a double-blind study, Clin. Pharmacol. Ther., 59: 458-468, 1996.

3147. Alexandrova, M., Kirov, D., and Douchlensky, I., Diphenylhydantoin (phenytoin) in the treatment of heroin withdrawal, Personal Communication, 2001.

3148. Sofuoglu, M., Pentel, P.R., Bliss, R.L., Goldman, A.I., and Hatsukami, D.K., Effects of phenytoin on cocaine self-administration in humans, Drug Alcohol Depend., 53: 273-75, 1999.

3149. Jaffe, J.H., Pharmacological agents in the treatment of drug dependence, Psychopharmacology: The Third Generation of Progress, 1605-16, Meltzer, H.Y., Ed., Raven Press, NY, 1987.

3150. De Sousa, A. and De Sousa, D.A., The management of heroin dependence, CME: IPS, 6: 39-48, 1986.

3151. Huang, M. and Li, J., The detoxificated effect of phenytoin on heroin addicts, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3152. Kasser, C., ASAM Clinical Practice Guideline: The Role of Phenytoin in the Management of alcohol Withdrawal Syndrome, Amer. Soc. Addiction Med.> (ASAM), 1997.

3153. Mayo-Smith, M.F., Cushman, P., Hill, A.J., Jara, G., Kasser, C., Kraus, M., Nauts, D., Saitz, R., Smith, J.W., Sullivan, J. et al., Pharmacological management of alcohol withdrawal, JAMA, 278(2):, 1997.

3154. Roder-Wanner, U.U.,Noachtar, S., and Wolf, P., Response of polygraphic sleep to phenytoin treatment for epilepsy. A longitudinal study of immediate, short- and long-term effects, Acta. Neurol. Scand., 76: 157-67, 1987.

3155. Wolf, P., Influence of antiepileptic drugs on sleep, in: Advances in Epileptology, Vol 16, Wolf, P., et al, eds., Raven Press, New York, 733-7, 1987.

3156. Liang, D., Zhaong, H., Xu, N., and Zhang, H., The effect of phenytoin on enuresis, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3157. Hudson, J.I. and Pope, H.J., The role of anticonvulsants in the treatment of bulimia, Use of Anticonvulsants in Psychiatry: Recent Advances, 141-54, McElroy, S.L. and Pope, H.G., Eds., Oxford Health Care Inc., Clifton, NJ, 1988.

3158. Adamska-Dyniewska, H., Effect of combined treatment with hydantoinal and cardiac glycosides on the dynamics of left ventricular contraction, Pol. Arch Med. Wewn., 43(1):985-9, 1969.

3159. Coltorti, F., Ivey, T.D., Bardy, G.H., and Greene, H.L., Double tachycardia following surgery for recurrent ventricular arrhythmias, G. Ital. Cardiol., 16: 522-526, 1986.

3160. Epstein, A.E., Plumb, V.J., Henthorn, R.W., and Waldo, A.L., Phenytoin in the treatment of inducible ventricular tachycardia: results of Electrophysiologic testing and long-term follow-up, Pace, 10(5): 1049-57, 1987.

3161. Vaksmann, G., Fournier, A., Davignon, A., Ducharme, G., Houyel, L., and Fouron, J.C., Frequency and prognosis of arrhythmias after operative "correction " of tetralogy of fallot, Am. J. Cardiol., 66: 346-49, 1990.

3162. Smithdeal, C.D., Prevention of cardiac arrhythmias during chemical face peeling (phenol peel arrhythmias), Personal Communication, 1992.

3163. Suarez-Kurtz, G., Meneges Lorga, A., and Moraes, F.D., Effects of phenytoin on the ventricular tachyarrhythmias of chronic chagas' disease, Int. J. Cardiol., 36: 81-86, 1992.

3164. De Paola, A.A., Gondin, A.A., Hara, V., and Mendonca, A., Medical treatment of cardiac arrhythmias in Chagas' heart disease, Sao Paulo Med. J., 113(2): 858-61, 1995.

3165. Jackson, L.K., Sustained and nonsustained ventricular tachycardia: genesis, significance, and management, Cardiovasc. Clin., 16(3): 83-100, 1986.

3166. Cain, M.E., Management of ventricular arrhythmias occurring in patients after myocardial infarction, Angiology, 39(3/2): 307-20, 1988.

3167. Vaksmann, G., Fournier, A., Van Doesburg, N.H., Kratz, C., Fouron, J.C., and Davingnon, A., Incidence and prognosis of Arrhythmias in post-operative tetralogy of fallot: long-term follow-up study, Circulation, 78(PT2): II-595, 1988.

3168. Kudenchuk, P.J., Kron, J., Walancie, C.G., Cutler, J.E., Griffith, K.K., and Mcanulty, J.H., Day-today reproducibility of antiarrhythmic tacharrhythmias drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease, Am. J. Cardiol., 66(7): 725-30, 1990.

3169. Kudenchuk, P.J., Halperin, B., Kron, J., Walance, C.G., Griffith, K.K., and Mcnulty, J.H., Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias: When is drug testing sufficient?, Am. J. Cardiol., 72(18):1400-5, 1993.

3170. Fisher, J.D., Krikler, D., and Hallidie-Smith, K.A., Familial polymorphic ventricular arrhythmias, J. Am. Coll. Cardiol., 34(7):2015-2022, 1999.

3171. Maxwell, L.G., Martin, L.D., and Yaster, M., Bupivacaine-induced cardiac toxicity in neonates: successful treatment with intravenous phenytoin, Anesthesiology, 80(3): 682-6, 1994.

3172. Vukmir, R.B. and Stein, K.L., Torsades de pointes therapy with phenytoin, Ann. Emerg. Med., 20(2): 198-200, 1991.

3173. Stratmann, H.G. and Kennedy, H.L., Torsades de pointes associated with drugs and toxins: Recognition and management, Am. Heart J., 113(6): 1470-82, 1987.

3174. Soffer, J., Dreifus, L.S., and Michelson, E.L., Polymorphous ventricular tachycardia associated with normal and long Q-T intervals, Am. J. Cardiol., 49: 2021-9, 1982.

3175. Ellenbogen, K.A., Wood, M.A., and Kontos, H.A., Management of refractory neurocardiogenic syncope, Ann. Intern. Med., 128:73, 1998.

3176. Betremieux, P., Lefrancois, C., Oriot, D., Rind, M.C., Dabadie, A., and Journal, H., Ischemic anoxia and status epilepticus in term neonates: Therapeutic approaches, Rev. Pediatr., 22: 243-252, 1986.

3177. Ogawa, A., Yoshimoto, T., Mizoi, K., Sugawara, T., Sakurai, Y., and Sato, H., Acute revascularization for progressing stroke, Acta. Neurochir. (Wien), 112: 100-105, 1991.

3178. Li, C. and Dong, W., Clinical efficacy of phenytoin and its effect on cerebral hemodynamics in patients with acute cerebral infarction, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3179. Bell, H.H., Dittmeier, G., and Martinez, L.M., Alteration of serum lipoproteins by phenytoin, Arteriosclerosis, 6: 545-6A, 1986

3180. McKenney, J.M., Petrizzi, K.S., Wright, J.T., Cooper, L.W., and Lambert, C.M., The effect of low phenytoin doses on HDL cholesterol, Arteriosclerosis, 8: 586A, 1988.

3181. Calandre, E.P., Sinues Porta, B., and Garcia de la Calzada, D., The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients, Epilepsia, 33(1): 154-157, 1992.

3182. McKenney, J.M., Petrizzi, K.S., Briggs, G.C., and Wright, J.T., The effect of low-dose phenytoin on high-density lipoprotein cholesterol, Pharmacotherapy, 12(3):183-188, 1992.

3183. Zhang, H., Liang, D., and Cai, Y., Clinical study on the efficacy of phenytoin in hyperlipemia, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3184. Franceschini, G., Werba, J.P., D'acquarica, A.L., Gianfranceschi, G., Michelagnoli, S., and Sirtori, C.R., Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia, Clin. Pharmacol. Ther., 57(4):434-40, 1995.

3185. Goerdt, C., Keith, M., and Rubins, H.B., Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol, J. Clin. Pharmacol., 35: 767-75, 1995.

3186. Goerdt, C., Bloomfield Rubins, H., Swaim, W., and Folsom, A., Can phenytoin lower plasma fibrinogen concentrations?, Thrombosis Res., 79(3):231-36, 1995.

3187. Liang, D., Xu, N., Zhang, H., Zhang, H., and Miao, J., A self-controlled study of phenytoin in the treatment of hyperlipemia, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3188. Miller, M., Burgan, R.G., Osterlund, L., Segrest, J.P., and Garber, D.W., A prospective randomized trial of phenytoin in nonepiletic subjects with reduced HDL cholesterol, Arteriorscl. Thromb. Vascul. Biol., 15(12):2151-56, 1995.

3189. Matsuda, H., Fukuchi, T., Onuma, T., Ishida, S., and Uesugi, H., Interictal cerebral and cerebellar blood flow in temporal lobe epilepsy as measured by a noninvasive technique using TC-99M HMPAO, Clin. Nucl. Med., 21(11):867-872, 1996.

3190. Wang, J., Paroxysmal kinesigenic choreoathetosis, Zhonghua Shen Jing Jing Shen Ke Za Zhi, 22(1):44-5, 63, 1989.

3191. Garg, R.K. and Shukla, R., Paroxysmal kinesiogenic chorioathetosis: A frequently misdiagnosed movement disorder, Indian J. Psychiatry, 35(2):137-38, 1993.

3192. Hayashi, R., Hanyu, N., Yahikozawa, H., and Yanagisawa, N., Ictal muscle discharge pattern and spect in paroxysmal kinesigenic choreoathetosis, Electromyogr. Clin. Neurophysiol., 37: 89-94, 1997.

3193. Fukuda, M., Hashimoto, O., Nagakubo, S., and Hata, A., A family with an atonic variant of paroxysmal kinesigenic choreoathetosis and hypercalcitoninemia, Mov. Disord., 14(2):342-344, 1999.

3194. Nair, K.R., Paroxysmal hypnogenic dystonia responsive to phenytoin, Mov.Disord., 5(2): 180-1, 1990.

3195. Baruah, J.K., Regional infusion of diphenylhydantoin (RID) in motor unit hyperexcitable states (MUHS), Neurology, 38(Sup 1): 308, 1988.

3196. Kurtzke, R., Lange, D.J., Trojaborg, W., Papadimitrou, A., Mills, K., Nresome-Davis, J., and Rowland, L.P., Isaacs syndrome without clinical fasciculation, Ann. Neurol., 26(1): 186, 1989.

3197. Oda, K., Fukushima, N., Shibasaki, H., and Ohnishi, A., Hypoxia-sensitive hyperexcitability of the intramuscular nerve axons in Isaacs' syndrome, Ann Neurol, 25: 140-145, 1989.

3198. Hahn, A.F., Parkes, A.W., Bolton, C.F., and Stewart, S.A., Neuromyotonia in hereditary motor neuropathy, J. Neurol. Neurosurg. Psychiatry, 54: 230-235, 1991.

3199. Chang, Y.J., Wu, C.L., Chen, R.S., and Lu, C.S., Case of Isaacs syndrome successfully treated with phenytoin, Taiwan I. Hsueh. Hui. Tsa. Chih., 92(11): 1010-2, 1993.

3200. De Oliveira, J.T. and Levy-Reis, I., Syndrome of continuous muscle fiber activity, Arq. Neuropsiquiatr, S2(1): 96-99, 1994.

3201. Jamieson, P.W. and Katirji, M.B., Idiopathic generalized myokymia, Muscle Nerve, 17(1): 42-51, 1994.

3202. Perini, M., Ghezzi, A., Basso, P.F., and Montanini, R., Association of neuromyotonia with peripheral neuropathy, myasthenia gravis and thymoma: a case report, Ital. J. Neurol. Sci., 15(6): 307-10, 1994.

3203. Lehkuniec, E., Micheli, F., De Arbelaiz, R., Torres, M., and Parasiso, G., Concurrent hypnogenic and reflex paroxysmal dystonia, Mov. Disord., 3(4): 290-94,1990.

3204. Gutmann, L. and Phillips, L.H., Myotonia congenital, Semin. Neurol., 11(3): 244-48, 1991.

3205. Pusponegoro, H.D., Zacharia, J., and Passat, J., Myotonia congenital (Thomsen's disease): report of five cases in a family, Paediatr. Indones., 31: 170-8, 1991.

3206. Russman, B., Diamond, B., De Vivo, D.C., Kula, R., Tsairis, P., et al., DMD Clin. Trials Study Group, Duchenne Muscular Dystrophy: an open label trial of prednisone, phenytoin and dantrolene, Ann. Neurol., 30(3): 486, 1991.

3207. Kwiecinski, H., Ryniewicz, B., and Ostrzycki, A., Treatment of myotonia with antiarrhythmic drugs, Acta Neurol. Scand., 86(4):371-375, 1992.

3208. Editor, Treatment of myotonia, Lancet, 1(8544): 1242-4, 1987.

3209. Kingston W.J. and Moxley, R.T., Treatment of muscular dystrophies and inflammatory myopathies, Clin. Neuropharmacol., 9(4):361-72, 1986.

3210. Phanthumchinda, K., Yodnoplaklao, P., Familial paroxysmal dyskinesia, J. Med. Assoc. Thai., 80(6):402-405, 1997.

3211. Siegal, T., Muscle cramps in the cancer patient: Causes and treatment, J. Pain Symp. Manage., 6(2): 84-91, 1991.

3212. Engel, A.G. and Banker, B.Q., Muscle pain, cramps, and fatigue, Myology Basic and Clinical, 1907-1922, McGraw-Hill Book Company, NY, 1987.

3213. Pierini, L.D., Albim, J., Fustinoni, O., and Vila, J.F., The stiff-man syndrome, Prensa. Med. Argent., 72(14): 489-91, 1985.

3214. Qi, L., Liu, D., Mong, W., Liu, Y., and Huang, M., The effect of phenytoin on 8 cases of restless legs, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3215. Dropcho, E.J. and Soong, S.J., Steroid-induced weakness in patients with primary brain tumors, Neurology, 41: 1235-39, 1991.

3216. Lewis, J.H., Hiccups. Causes and cures, Curr. Ther., 28: 169-173, 1987.

3217. Chen, T., et al., The effect of phenytoin on five cases with intractable hiccups, West China Med. J., 7(1): 61-62, 1992.

3218. Lipsky, M.S., Chronic hiccups, Am. Fam. Physician, 34: 173-7, 1986.

3219. Kobayashi, I., Suzuki, H., Kondo, T., Yamauchi, T., Ohta, Y., and Yamabayashi, H., A case report of diaphragmatic flutter, Nippon Kyobu Shikkan Gakkai Zasshi, 28(5): 777-80, 1990.

3220. Minaker, K.L., Flier, J.S., Landsberg, L., Young, J.B., Moxley, R.T., Kingston, W.J., Meneilly, G.S., and Rowe, J.W., Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and icral hypertrophy, Arch. Neurol., 46: 981-5, 1989.

3221. Jansen, P.H., Joosten, E.M., and Vingerhoets, H.M., Muscle cramp as a feature neuromuscular disease - five neuromuscular disorders, accompanied by frequent muscle cramps, Acta. Neurol. Belg., y2(3): 138-147, 1992.

3222. Kuo, W.S., Ho, S.T., Hu, O.Y., Li, C.H., and Hwing, C.S., The study of pretreatment with diphenylhydantoin or d-tubocurarine on succinylcholine-induced adverse effects, Anaesthesiol. Sin., 28(3): 323-8, 1990.

3223. Swerdlow, M., Anticonvulsants in the therapy of neuralgic pain, Pain Clinic, 1(1): 9-19, 1986.

3224. Mauskop, A., Trigeminal neuralgia (tic douloureux), J. Pain. Symp. Manage., 8(3): 148-154, 1993.

3225. Qi, L., Liu, C., and Huang, M., A double-blind study of the effect of phenytoin ion trigeminal neuralgia, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3226. Cheshire, W.P., Fosphenytoin: An intravenous option for the management of trigeminal neuralgia crisis, J. Pain Symp. Manage., 21:506-510, 2001.

3227. Perkin, G.D., Trigeminal neuralgia, Curr. Treatment Options Neurol., 1(5):458-465, 1999.

3228. Cheng, T.M., Cascino, T.L., and Onofrio, .B.M, Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors, Neurology, 43(11):2298-302, 1993.

3229. Turp, J.C. and Gobetti, J.P., Trigeminal neuralgia - an update, Compend. Contin. Educ. Dent., 21(4):279-82, 2000.

3230. Wiffen, P., Collins, S., Mcquay, H., Carroll, D., Jasas, A., and Moore, A, Anticonvulsant drugs for acute and chronic pain, Cochrane Database of Systematic Reviews, (3):CD001133, 2000.

3231. Zakrzewska, J.M., Medical management of trigeminal neuralgia, Br. Dent. J.,168: 399-401, 1990.

3232. Zeidman, S.M. and North, R.B., Trigeminal neuralgia, Conn's Current Therapy, 912-914, Rakel, R.E., Ed., W.B. Saunders, Philadelphia, PA, 1994.

3233. Rozen, T.D., Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia, Headache, 1:S25-32, 2001.

3234. Sindrup, S.H. and Jensen, T.S., Pharmacotherapy of trigeminal neuralgia, Clin. J. Pain, 18:22-27, 2002.

3235. Mcquay, H., Carroll, D., Jadad, A.R., Wiffen, P., and Moore, A, Anticonvulsant drugs for management of pain: A systematic review, Br. Med. J., 311:1047-1052, 1995.

3236. Kinzbrunner, B.M., Aanticonvulsant drugs reduce pain in trigeminal neuralgia and diabetic neuropathy and are effective for migraine prophylaxis [Therapeutics], Acp. J. Club, 124:35, 1996.

3237. Rouveix, B., Bauwens, M.C., and Giroud, J.P., Treatment of different types of pain, Bull. Acad. Natl. Med., 183(5):889-901, 1999.

3238. Metheetrairut C. and Brown, D.H., Glossopharyngeal neuralgia and syncope secondary to neck malignancy, J. Ootolaryngol., 22(1):18-20, 1993.

3239. Weil, A.A., Observations on dysrhythmic migraine, J. Nerv. Ment. Dis., 134: 277-81, 1962.

3240. Smyth, V.O. and Winter, A.L., Dysrhythmic migraine, Electroencephalogr. Clin. Neurophysiol., 15: 912-3, 1963.

3241. Raskin, N.H. and Appenzeller, O., Migraine: Treatment and clinical pharmacology, Headache, 111-171, W. B. Saunders, Philadelphia, PA, 1980.

3242. Raffaelli, E., Martins, O.J., and Dagua Filho, A., A role for anticonvulsants in migraine, Funct. Neurol., 1(4): 495-8, 1986.

3243. Robbins, L., Post-traumatic headache with scintillating scotoma treated with phenytoin (dilantin), Headache, 29: 515-516, 1989.

3244. Wang, J., Qi, L., Lu, Q., and Huang, M., The effect of phenytoin on migraine, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3245. Mathew, N.T., Headache, Conn's Current Therapy, 864-879, Rakel, R.W., Ed., W. B. Saunders, Philadelphia, PA, 1994.

3246. Swerdlow, M., The use of anticonvulsants in the management of cancer pain, The Pain Clinic I, Proceedings of the First International Symposium, 61-70, Erdmann, W., et al, Eds., VNU Science Press, Utrecht, 1985.

3247. Skeleton, III, W.P. and Khouzam Skeleton, N., Neuroleptics in painful thiamine deficiency neuropathy, South Med. J., 84(11):1362-63, 1991.

3248. Aldrete, J.A. and Ghaly, R., Delayed sympathetically maintained pain caused by electrical burn at the current's entry and exit sites, J. Pain Symp. Manage., 9(8):541-43, 1994.

3249. Wiffen, P., McQuay, H., Carroll, D., Jadad, A., and Moore, A., Anticonvulsant drugs for the management of acute and chronic pain, Cochrane Database of Systematic Reviews, 4, 1998.

3250. Sindrup, S.H. and Jensen, T.S., Pharmacologic treatment of pain in polyneuropathy, Neurology, 55(7):915-920, 2000.

3251. Ross, E.L., The evolving role of antiepileptic drugs in treating neuropathic pain, Neurology, 55(S1):S41-S46, 2000.

3252. Tanelian, D.L. and Victory, R.A., Sodium channel-blocking agents, Pain Forum, 4(2):75-80, 1995.

3253. Jensen, T.S., Anticonvulsants in neuropathic pain: Rationale and clinical evidence, Eur. J. Pain, 6:61-68, 2002.

3254. Carter, G.T. and Galer, B.S., Advances in the management of neuropathic pain, Arch. Phys.Med. Rehabil., 12(2):447-459, 2001.

3255. Tremont-Lukats, I.W., Megeff, C. and Backonja, M.M., Anticonvulsants for neuropathic pain syndromes, Drugs, 60(5):1029-52, 2000.

3256. Chojnowska, E., Which intravenous sodium channel blocker for neuropathic pain? (Letter), Anesth. Analg., 90(4):1007-1008, 2000.

3257. Belgrade, M.J. and Lev, B.I., Diabetic neuropathy - helping patients cope with their pain, Postgrad. Med., 90(5): 263-70, 1991.

3258. Thomas, P.K. and Scadding, J.W., Treatment of pain in diabetic neuropathy, Diabetic Neuropathy, 216-22, Dyck, P.J., et al, Eds., W. B. Saunders, Philadelphia, PA, 1987.

3259. Kumudchandra, J.S. and Bernhard, G.C., The arthropathy of Fabry disease, Arthritis Rheum., 22(7): 781-3, 1979.

3260. Thomas, J. and Muthuswami, T.C., Diphenylhydantoin in post-herpetic neuralgia, Indian J. Dermatol. Venereol. Leprol., 54: 303-304, 1988.

3261. Thomas, J. and Muthuswami, T.C., Diphenylhydantoin in post-herpetic neuralgia - A controlled study, Presented at the XVIth National Conference of Indian Association of Dermatologists, Venereologists and Leprologists, Calcutta, India, 1988.

3262. Watson, P.N. and Evans, R.J., Postherpetic neuralgia - A review, Arch. Neurol., 43:836-40, 1986.

3263. McCleane, G.J., Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blind, placebo-controlled, crossover study, Anesth. Analg., 89:985-988, 1999.

3264. Ashburn, M.A. and Staats, P.S., Management of chronic pain, Lancet, 353:1865-1869, 1999.

3265. France, R.D. and Krishnan, K.R., Psychotropic drugs in chronic pain, 323-74, Chronic Pain, France, R.D. and Krishnan, K.R., Eds., American Psychiatric Press, Washington, DC, 1988.

3266. Iacono, R.P., Linford, J., and Sandyk, R., Pain management after lower extremity amputation neurosurgery, Neurosurgery, 20: 496-500, 1987.

3267. Chaturvedi, S.K., Phenytoin in reflex sympathetic dystrophy, Pain, 36: 379-380, 1989.

3268. Koman, L.A., Barden, A., Smith, B.P., Pollock, F.E., Sinai, S., and Poehling, G.G., Reflex sympathetic dystrophy in an adolescent, Foot and Ankle, 14(5): 273-77, 1993.

3269. Webb, J. and Kamali, F., Analgesic effects of lamotrigine and phenytoin on cold-induced pain: a crossover placebo-controlled study in healthy volunteers, Pain, 76: 357-363, 1998.

3270. Shah, S. and Sharma, K., Use of phenytoin in head and neck cancer pain, Sixth World Congress on Pain, Adelaide, Australia, 1-6, April 1990, Pain, Suppl 5: S357, 1990.

3271. Bhatia, M.T., Simplified approach for relief of terminal cancer pain with phenytoin sodium, Antiseptic, 88(1): 18-22, 1991.

3272. Bhatia, M.T., Anticonvulsant alone in the relief of cancer pain, J. Indian Med. Assoc., 90(11): 301-2, 1992.

3273. Bhatia, M.T., Combination of dilantin with aspirin in relief of terminal cancer pain, Personal Communication, 1-3, 1992.

3274. Yajnik, S., Singh, G.P., Singh, G., and Kumar, M., Phenytoin as co-analgesic in cancer pain, J. Pain Symp. Manage., 7(4): 209-213, 1992.

3275. Chang, V.T., Intravenous phenytoin in the management of crescendo pelvic cancer-related pain, J. Pain Symp. Manage., 13(4):238-240, 1997.

3276. Portenoy, R.K. and Lesage, P., Management of cancer pain, Lancet, 353:1695-1700, 1999.

3277. Domachowska, W., Clinical use of phenytoin 5% oral mucosa disorders and periodontitis, Personal Communication, 2001.

3278. Domachowska, W., Clinical applications of phenytoin sodium (PHT), Personal Communication, 2001.

3279. Savini, E.C., Poitevin, R., and Payen, J., Topical application of hydantoins in gingival disorders, in: Phenytoin-Induced Teratology and Gingival Pathology, Hassell, T.M., et al, eds., Raven Press, New York, 215-222, 1980.

3280. De Silva, G.S. and Rahulan, T., Effects of topical application of sodium diphenylhydantoin on chronic ulcers, Presented at the 48th Annual Sessions of the Galle Clinical Society, Aug. 1988.

3281. Mahapatra, K.C., Clinical trial of diphenylhydantoin or dilantin (DPH) in leprosy, Damien Institute, Orissa, India, February, 1988.

3282. Pasolini, G., Pancera, C., Manganoni, A.M., Cetta, G., and Zanaboni, G., Leg ulcers due to prolidase deficiency, J. Ital. Dermatol. Venereol., 123: 493-6, 1988.

3283. Smith, B.H., Moore, M., Jain, K., The First International Conference on the Uses of Phenytoin in Dermatology, Dec.1987, Int. J. Dermatol., 27: 528-30, 1988.

3284. De Leon, M.E. and Leon, G., Leg ulcers: Study to evaluate the efficacy and tolerance of topical phenytoin in the treatment of leg ulcers, Presented to the XIV Congreso Mexicano de Dermatologia, Villahermosa, Tabasco, Mexico, October 31-November 4, 1989, Janssen Pharmaceutica, 1989.

3285. El-Gindy, M., El-Zawarhry, M.D., Abdel-Latif, A., Farid, M., Horeia, H., El-Doseky, I., Abo-Hashem, E., and El-Zayat, S.G., Effect of topical phenytoin on healing of chronic venous leg ulcers, Personal Communication, 1989.

3286. El-Zayat, S.G., Preliminary experience with topical phenytoin in wound healing in a war zone, Milit. Med., 154(4): 178-80, 1989.

3287. Modaghegh, S., Salehian, B., Tavassoli, M., Djamshidi, A., and Shiekh Rezai, A., Use of phenytoin in healing of war and non-war wounds: A pilot study of 25 cases, Int. J. Dermatol., 28(5): 347-50, 1989.

3288. Bansal, N.K. and Mukul, A.K., Role of topical diphenylhydantoin in trophic ulcers of leprosy patients, Presented at the 18th National Conference of the Indian Association of Dermatologists, Venereologists and Leprologists, SMS Medical College & Hospital, Jaipur, India, 1990.

3289. Bogaert, H., Saleta, B., Sanchez, E., and Garcia, B., Trophic leprosy ulcers: treatment with topical and systemic phenytoin, Int. J. Dermatol., 29(2): 156-157, 1990.

3290. Bogaert, H. and Sanchez, E., Lichen planus: Treatment of thirty cases with systemic and topical phenytoin, Int. J. Dermatol., 29(2): 157-158, 1990.

3291. Saul, A., Ortega, M.E., and Leon, G., Phenytoin in the treatment of leg ulcers, Presented at the International Symposium on Dermato-Therapeutics, Merida, Mexico, March 1990.

3292. Lodha, S.C., Lohiya, M.L., Vyas, M.C., Bhandari, S., Goyal, R.R., and Harsh, M.K., The role of phenytoin in the healing of large abscess cavities, Br. J. Surg., 78(1): 105-08, 1991.

3293. Malhotra, Y.K. and Amin, S.S., Role of topical phenytoin in trophic ulcers of leprosy in India, Int. J. Lepr., 59(2): 337-8, 1991.

3294. Muthukumarasamy, M.G., Sivakumar, G., and Manoharan, G., Topical phenytoin in diabetic foot ulcers, Diabetes Care, 14: 909-911, 1991.

3295. Xu, N., Liang, D., Zhang, H., and Zhang, H., The effect of phenytoin on refractory ulcers in gout, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3296. Xu, N., et al., The effect of phenytoin on refractory ulcers in gout, West China Med. J., 7(4): 408-10, 1992.

3297. Bansal, N.K. and Mukul, A.K., Comparison of topical phenytoin and normal saline in the treatment of chronic trophic ulcers in leprosy, Int. J. Dermatol., 32(3): 210-213, 1993.

3298. Desai, N.C., Desai, S., Assie, S., and Desai, R., Topical application of phenytoin in the treatment of chronic corneal ulcers, Personal Communication, 1993.

3299. Menezes, J., Rajendran, A., Jacob, A.J., and Vaz, M., The use of topical phenytoin as an adjunct ti immobilization in the treatment of trophic leprosy ulcers, Southeat Asian J. Trop. Med. Public Health, 24(2): 340-42, 1993.

3300. Pendse, A.K, Sharma, A., Sodani, A., and Hada, S., Topical phenytoin in wound healing, Int. J. Dermatol., 32(3): 214-217, 1993.

3301. Yadav, J.K., Singhvi, A.M., Kumar, N., and Garg, S., Topical phenytoin in the treatment of split-thickness skin autograft donor sites: a comparative study with polyurethane membrane drape and conventional dressing, Burns, 19(4): 306-10, 1993.

3302. Zhang, H.M., Liang, D., and Xu, N., The effect of topical use of phenytoin on oral mucosal ulcers in leukemia, Presented at the Third China-Japan Joint Meeting on Pharmacology, Beijing, China, May 1993.

3303. Bansal, N.K. and Mukul, M.D., Comparison of topical phenytoin with normal saline in the treatment of chronic trophic ulcers in leprosy, Dermatol. Digest, 1994.

3304. Lewis, W.G. and Rhodes, R.S., Systemic absorption of topical phenytoin sodium, Ann. Pharmacother., 28(7-8): 961, 1994.

3305. Liu, B., Song, X., Yuan, H., Lou, X., Lu, C., Yu, S., Jia, G., and Zhu, X., Clinical observation of local application of phenytoin in treating the ulcers of leprosy, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3306. Liu, B., Xiang, S., and Honglin, Y., The effect of local application of phenytoin in treating skin ulcers, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3307. Tang, L., Yan, J., Huang, X., Fang, R., and Shen, B., Application of phenytoin on wound healing - clinical observation of 37 cases, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3308. Anstead, G.M.H., Art, L.M., Sunahara, J.F., and Liter, M.E., Phenytoin in wound healing, Ann. Pharmacother., 30:768-774, 1996.

3309. O'Toole, M.J., Kolb, J.E., Lindblad, W.J., Cohen, I.K., McKneally, M.F., Pneumothorax and wound dehiscence related to collagenase deregulation: Treatment with diphenylhydantoin, Ann. Thorac. Surg., 61(6):1646-50, 1996.

3310. Adjei, O., Evans, M.R., and Asiedu, A., Phenytoin in the treatment of Buruli ulcer, Trans. R. Soc. Trop. Med. Hyg., 92(1): 108-109, 1998.

3311. Oluwatosin, O.M., Olabanji, K.J., Oluwatosin, O.A., Tijani, L.A., Onyechi, H.U., A comparison of topical honey and phenytoin in the treatment of chronic leg ulcers, Afr. J. Med. Sci., 29:31-34, 2000.

3312. Rhodes, R.S., Heyneman, C.A., Culbertson, V.L., Wilson, S.E., and Phatak, H.M., Topical phenytoin treatment of stage II decubitus ulcers in the elderly, Ann. Pharmacother., 35(6): 675-681, 2001.

3313. Nyawawa, E.T.M., The use of topical diphenylhydantoin in the treatment of non-malignant chronic leg ulcers as seen at Muhimbili National Hospital, Dar es Salaam, Tanzania, Doctoral Thesis, Muhimbili National Hospital, Dar es Saalam, 2002.

3314. Carneiro, P.M.R. and Nyawawa, E.T., Topical phenytoin versus eusol in the treatment of non-malignant chronic leg ulcers, East Afr. Med. J., 80(3): 124-9, 2003.

3315. Klutse, E.Y., Adjei, O., Ampadu, E., and Arthur, L., Management of Buruli ulcer cases with topical application of phenytoin powder, Presented at the 6th WHO Advisory Group Meeting on Buruli Ulcer, March 10-13, 2003.

3316. Amin, S.S., Study of effect of topical diphenylhydantoin sodium on non healing ulcers in leprosy and other diseases, Doctoral Thesis, University of Rajasthan, Jaipur, India 1988.

3317. Margolis, D.J. and Lewis, V.L., A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers, Dermatol. Surg., 21(2):145-8, 1995.

3318. Johnson, T.J., Use of topical phenytoin for wound care, SD J. Med., 51(10):387-88, 1998.

3319. Mirza, R.A., Accelerated callous formation with phenytoin sodium, J. Pakistan. Med. Assoc., 37: 310, 1987.

3320. Lodha, S.C., New application of an old drug: topical phenytoin in burns, J. Burn Care Rehabil., 12(1): 96, 1991.

3321. Bajaj, S.P., Nayar, R., and Bhandari, P.S., Topical use of phenytoin in the management of acute burns, Personal Communication, 1994.

3322. Kang, S., Clinical observation of phenytoin in burn treatment, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3323. Pu, Q., Tang, X., Jiang, F., Li, B., and Cheng, F., Clinical study of zinc phenytoin in the treatment of burn wounds, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3324. Carneiro, P.M.R., Rwanyuma, L.R.J., and Mkony, C.A., A comparison of topical phenytoin with silverex in the treatment of superficial dermal burn wounds, Cent. Afr. J. Med., 48(9/10): 105-8, 2002.

3325. Lohiya, M.L., Effect of dilantin sodium in surgical practice with special reference to abscess cavities and burn lesions, Doctoral Thesis, University of Rajasthan, Jaipur, India, 1988.

3326. Rwehumbiza, L. and Rwanyuma, J., A comparison of topical diphenylhydantoin with a standard therapy in burn wounds at Muhimbili National Hospital, Dar es Saalam, Tanzania, Doctoral Thesis, 2001.

3327. Jayaraman, M., Ilangovan, G., Abdul Razack, A., and Muthuswami, T.C., Diphenylhydantoin in localized scleroderma, Presented at the 18th National Conference of the Indian Association of Dermatologists, Venereologists and Leprologists, SMS Medical College & Hospital, Jaipur, India, 1990.

3328. Liu, B. and Song, X., The effect of phenytoin on scleroderma, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3329. Eubanks, L.E., McBurney, E.I., Galen, W., and Reed, R., Linear scleroderma in children, Int. J. Dermatol., 35(5):330-6, 1996.

3330. Yamanaka, C.T. and Gibbs, N.F., Trauma-induced linear scleroderma, Cutis, 63:29-32, 1999.

3331. Cunnane, S.C., Kent, E.T., McAdoo, K.R., Caldwell, D., Lin, A.N., and Carter, D.M., Abnormalities of plasma and erythrocyte essential fatty acid composition in epidermolysis bullosa: Influence of treatment with diphenylhydantoin, J. Invest. Dermatol., 89: 395-9, 1987.

3332. Fine, J.D. and Johnson, L., Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa, Arch. Dermatol., 124: 1402-6, 1988.

3333. Pappu-Katikaneni, L.D. and Wiest, D.B., Phenytoin (PHT) dosing requirements and blister fluid concentrations (BFC) in a junctional epidermolysis bullosa (JEB) patient, Pediatr. Res., 23(4):262A, 1988.

3334. Lin, A.N., Stern, R.S., Caldwell-Brown, D., and Carter, D.M., Phenytoin for recessive dystrophic epidermolysis bullosa, Clin. Res., 37(2): 625A, 1989.

3335. Caldwell-Brown, D., Stern, R.S., Lin, A.N., and Carter, D.M., Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa, N. Engl. J. Med., 327(3): 163-167, 1992.

3336. Masgrau-Peya, E., Lacour, M., and Salomon, D., Topical phenytoin accelerates healing in epidermolysis bullosa simplex, Dermatology, 190(3):254, 1995.

3337. Fine, J.D., Epidermolysis bullosa, clinical aspects, pathology, and recent advances in research, Int. J. Dermatol., 25: 143-57, 1986.

3338. Nawaz, A., Matta, H., Jacobsz, A., and Al-Salem, A., Congenital pyloric atresia and junctional epidermolysis bullosa: a report of two cases, Pediatr. Surg. Int., 16(3): 206-8, 2000.

3339. Fine, J.D. and Johnson, L., Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa (JEB), J. Clin. Pharmacol., 27(9): 723, 1987.

3340. Pearson, R.W. and Paller, A.S., Dermolytic (dystrophic) epidermolysis bullosa inverse, Arch. Dermatol., 124: 544-7, 1988.

3341. Kern, I.B., Eisenberg, M., and Willis, S., Management of oesophageal stenosis in epidermolysis bullosa dystrophica, Arch. Dis. Child., 64: 551-6, 1989.

3342. Popov, N., Contemporary problems in epidermolysis bullosa in view of four cases under observation, Pediatriya (Sofia), 27(4): 64-72, 1988.

3343. Talas, G., Adams, T.S.T., Eastwood, M., Rubio, G., and Brown, R.A., Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels, Int. J. Biochem. Cell Biol., 29(1):261-270, 1997.

3344. Rodriguez-Castellanos, M.A., Barba-Rubio, J., and Barba Gomez, J.F., Phenytoin: Its use in the treatment of discoid lupus erythematosus, Presented at the Mexican Congress of Dermatology, November 1989.

3345. Rodriguez-Castellanos, M.A., Barba-Rubio, J., Barba Gomez, J.F., and Gonzalez-Mendoza, A., Phenytoin in the treatment of discoid lupus erythematosus, Arch. Dermatol., 131(5):620-1, 1995.

3346. Talas, G., Brown, R.A., and McGrouther, D.A., Role of phenytoin in wound healing - a wound pharmacology perspective, Biochem. Pharmacol., 57(10): 1985-94, 1999.

3347. Scheinfeld, N., Phenytoin in cutaneous medicine: its mechanisms and side effects, Dermatol. Online J., 9(3):6, 2003.

3348. Jain, S. and Jain, K.C., Effect of phenytoin sodium in the management of poorly controlled bronchial asthma at a rural health center in Phalodi, Rajasthan, India, J. Asthma, 28(3): 201-11, 1991.

3349. Anonymous, Diarrhea in the diabetic patient and phenytoin, Bol. Hosp. Juan de Dios, 33(5): 311, 1986.

3350. Lahtela, J.T., Effect of long-term anticonvulsant therapy on glucose metabolism in humans, Epilepsia, 27(6): 711-17, 1986.

3351. Lowe, K.G. and Wilkins, B.H., Phenytoin in the management of severe acute SIADH, J. Paediatr. Child Health, 31(2):155, 1995.

3352. Sone, H., Okuda, Y., Bannai, C., Suzuki, S., Yamaoka, T., Asakura, Y., Kawakami, Y., Odawara, M., Matsushima, T., and Kawai, K., Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and Gerhardt syndrome associated with Shy-Drager syndrome, Intern. Med., 33(12):773-8, 1994.

3353. Vieweg, W.V., Weiss, N.M., David, J.J., Rowe, W.T., Godleski, L.S., and Spradlin, W.W., Treatment of psychosis, intermittent hyponatremia, and polydipsia (PIP syndrome) using lithium and phenytoin, Biol. Psychiatry, 23: 25-30, 1988.

3354. Ryabtzeva, I.T., Medvedva, T.G., and Shapovalova, K.A., Phenytoin in hypothalamic disorders, Int. J. Psychophysiol., 18(2):145, 1994.

3355. Ludolph, A.C. and Elger, C.E., Successful treatment of a case of Kleine-Levin syndrome with diphenylhydantoin, Neurology, 37(SUP1): 102, 1987.

3356. Brunet, M., Rodamilans, M., Martinez-Osaba, M.J., Santamaria, J., To-Figueras, J.,Torrra, M., Cobella, J., and Rivera, F., Effects of long-term antiepileptic therapy on the catabolism of testosterone, Pharmacol. Toxicol., 76:371-75, 1995.

3357. Duncan, S., Blacklaw, J., Beastall, G.H., and Brodie, M.J., Antiepileptic drug therapy and sexual function in men with epilepsy, Epilepsia, 40(2): 197-204, 1999.

3358. Herzog, A.G., Altered reproductive endocrine regulation in men with epilepsy: Implications for reproductive function and seizures, Ann.Neurol., 51(5):539-542, 2002.

3359. Lucas, L.S. and Jordan, E.T., Phenytoin as an alternative treatment for preeclampsia, J. Obstet. Gynecol., Neonatal. Nurs., 26: 263-269, 1997.

3360. Sungani, F.C.M., Malata, A., and Masanjika, R., Pre-eclampsia/eclampsia: a literature review, Cent. Afr. J. Med., 44(10): 261-263, 1998.

3361. Bhagwanjee, S., Paruk, F., Moodley, J., and Muckart, D.J.J., Intensive care unit morbidity and mortality from eclampsia: an evaluation of the acute physiology and chronic health evaluation II score and the Glasgow coma scale score, Crit. Care Med., 28(1): 120-124, 2000.

3362. Duley, L., Gulmezoglu, A.M., and Henderson-Smart, D.J., Anticonvulsants for women with pre-eclampsia [Systematic Topic Review], Cochrane Database of Systematic Reviews, 4, 1998.

3363. Young, G.L., Magnesium sulphate prevented eclampsia better than phenytoin, [Therapeutics], Evidence-Based Medicine, 1: 45, 1996.

3364. Young, G.L., Magnesium sulphate was superior to diazepam or phenytoin for eclampsia [Therapeutics], Evidence-Based Medicine, 1: 44, 1996. v

3365. Sawhney, H., Sawhney, I.M.S., Mandal, R., Subramanyam, and Vasishta, K., Efficacy of magnesium sulphate and phenytoin in the management of eclampsia, J. Obstet. Gynaecol. Res., 25(5): 333-338, 1999.

3366. Naidu, S., Moodley, J., Botha, K., and Mcfadyen, L., The efficacy of phenytoin in relation to serum levels in severe pre-eclampsia and eclampsia, Br. J. Obstet. Gynaecol., 99: 881-886, 1992.

3367. Chatterjee, A. and Mukheree, J., Comparative study of different anticonvulsants in eclampsia, J. Obstet. Gynaecol., 23(3):289-293, 1997. v

3368. Lucas, M.J., DePalma, R.T., Peters, M.T., Leveno, K.J., Person, D., and Cunningham, F.G., A simplified phenytoin regimen for preeclampsia, Am. J. Perinatol., 11(2):153-56, 1994.

3369. Robson, S.C., Redfern, N., Seviour, J., Campbell, M., Walkinshaw, S., Rodeck, C., and DeSwiet, M., Phenytoin prophylaxis in severe pre-eclampsia and eclampsia, Br. J. Obstet. Gynaecol., 100(7): 623-28, 1993.

3370. Guzman, E.R., Conley, M., Stewart, R., Ivan, J., Pitter, M., and Kappy, K., Phenytoin and magnesium sulfate effects on fetal heart rate assessed by computer analysis, Obstet. Gynecol., 82(3):375-379, 1993.

3371. Friedman, S.A., Lim, K.H., Baker, C.A., and Repke, J.T., Phenytoin versus magnesium sulfate in pre-eclampsia: A pilot study, Am. J. Perinatol., 10(3): 233-8, 1993.

3372. Mathias, L., Nobile, L., Barros, A.D., and Neme, B., The use of phenylhydantoin in eclamptic refractory convulsions, J. Bras. Ginec., 92(3): 153-156, 1982.

3373. Lucas, M.J., Leveno, K.J., and Cunningham, F.G., A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia, N. Engl. J. Med., 333(4):201-5, 1995.

3374. Mandelkern, D. and Burger, A., Cortical blindness in postpartum pre-eclampsia progressing to eclampsia, Mt. Sinai J. Med., 59(1): 72-74, 1992.

3375. Appleton, M.P., Kuehl, T.J., Raebel, M.A., Adams, H.R., Knight, A.B., and Gold, W.R., Magnesium sulfate versus phenytoin for seizure prophylaxis in pregnancy-induced hypertension, Am. J. Obstet. Gynecol., 165: 907-13, 1991.

3376. Kaplan, P.W., Lesser, R.P., Fisher, R.S., Repke, J.T., and Hanley, D.F., A continuing controversy: Magnesium sulfate in the treatment of eclamptic seizures, Arch. Neurol., 47: 1031-1032, 1990.

3377. Coyaji, K.J. and Otiv, S.R., Single high dose of intravenous phenytoin sodium for the treatment of eclampsia, Acta. Obstet. Gynecol. Scand., 69: 115-18, 1990.

3378. Maheshwari, J.R., Desai, S.V., Hansotia, M.D., and Walvekar, V.R., Anticonvulsant therapy in eclampsia, J. Postgraduate Med., 35(2): 66-69, 1989.

3379. Dommisse, J, Phenytoin sodium and magnesium sulphate in the management of eclampsia, Br. J. Obstet. Gynaecol., 97: 104-109, 1990.

3380. Kaplan, P.W., Lesser, R.P., Fisher, R.S., Repke, J.T., and Hanley, D.F., No, Magnesium sulfate should not be used in treating eclamptic seizures, Arch. Neurol., 45: 1361-64, 1988.

3381. Slater, R.M., Wilcox, F.L., Donnai, P., Smith, W.D., Richardson, T., The use of a high dose phenytoin regime in pre-eclampsia, Clin. Exp. Hypertens., 6(1): 169,1987.

3382. Hauswald, M., Cortical blindness and late postpartum eclampsia, Am. J. Emerg. Med., 5: 130-2, 1987.

3383. Slater, R.M., Smith, W.D., Patrick, J., Mawer, G.E., Wilcox, F.L., Donnai, P., Richardson, T., D'Souza, S.W., and Anderton, J.M., Phenytoin infusion in severe pre-eclampsia, Lancet, 1(8547):1417-21, 1987.

3384. Moosa, S.M. and El-Zayat, S.G., Phenytoin infusion in severe pre-eclampsia, Lancet, 2(8568): 1147-8, 1987.

3385. Ryan, G., Lange, I.R., and Naugler, M.A., Clinical experience with phenytoin prophylaxis in severe pre-eclampsia, Am. J. Obstet. Gynecol., 161: 1297-1304, 1989.

3386. Jagoda, A. and Riggio, S., Emergency department approach to managing seizures in pregnancy, Ann. Emerg. Med., 20: 80-85, 1991.

3387. Cincotta, R. and Ross, A., A review of eclampsia in Melbourne: 1978-1992, Aust. N.Z. J. Obstet. Gynaecol., 36:264-267, 1996.

3388. Naidu, S. and Moodley, J., Efficacy of phenytoin in eclampsia, Int. J. Gynaecol. Obstet., 56:275-276, 1997.

3389. Lain, K.Y. and Roberts, J.M., Contemporary concepts of the pathogenesis and management of pre-eclampsia, JAMA, 287:3183-3186, 2002.

3390. Mahmoudi, N., Graves, S., Solomon, C., Repke, J.T., and Seely, E.W., Eclampsia: A 13 year experience at a United States tertiary care center, J. Women's Health Gen. Based Med. 8(4):495-500, 1999.

3391. Hutton, J.D., James, D.K., Stirrat, G.M., Douglas, K.A., and Redman, C.W., Management of severe pre-eclampsia and eclampsia in the UK, Br. J. Obstet. Gynaecol., 99(7): 554-556, 1992.

3392. Sibai, R.M., Magnesium sulfate is the ideal anticonvulsant in pre-eclampsia-eclampsia, Am. J. Obstet. Gynecol., 162: 1141-45, 1990.

3393. Borsch, G. and Ricken, D., Undesirable drug effects on the gastrointestinal tract, Dtsch. Med. Wochenschr., 114(5): 184-7, 1989.

3394. Hutton, J.D., Nghan Kee, D.G., and Wilcox, F.L., New Zealand Obstetricians' management of hypertension in pregnancy - A questionnaire survey, Aust. N. Z. J. Obstet. Gynaecol., 29: 5-8, 1989.

3395. Slater, R.M., Smith, W.D., Patrick, J., Mawer, G.E., Wilcox, F.L., Donnai, P., Richardson, T, D'Souza, S.W., Anderton, J.M., Phenytoin infusion in severe pre-eclampsia, Lancet, (8547):1417-21, 1987.

3396. Eclampsia Trial Collaborative, Which anticonvulsants for women with eclampsia? Evidence from the Collaborative Eclampsia Trial, Lancet, 345:1455-1463, 1995.

3397. Duley, L., Gulmezoglu, A.M., and Henderson-Smart, D.J., Anticonvulsants for women with pre-eclampsia (Cochrane Review), Cochrane Database of Systematic Reviews, (2):CD000025, 2000.

3398. Kaplan, P.W., Neurologic issues in eclampsia, Rev. Neurol. (Paris),155:5;335-341, 1999.

3399. Rey, E., Lelorier, J., Burgess, E., Lange, I.R., and Leduc, L., Review: Pharmacologic treatment of hypertension during pregnancy reduces perinatal deaths and severe maternal hypertension [Therapeutics], Acp. J. Club, 128:63, 1998.

3400. Combs, C.A., Walker, C., Matlock, B.A., and Crombleholme, W., Transient diabetes insipidus in pregnancy complicated by hypertension and seizures, Am. J. Perinatol., 7(3): 287-89, 1990.

3401. Duley, L. and Henderson-Smart, D., Magnesium sulphate versus phenytoin for eclampsia [Systematic Topic Review], Cochrane Database of systematic Reviews, 4, 1998.

3402. Naidu, S., Payne, A.J., Moodley, J., Hoffmann, M., and Gouws, E., Randomised study assessing the effect of phenytoin and magnesium sulphate on maternal cerebral circulation in eclampsia using transcranial Doppler ultrasound, Br. J. Obstet. Gynaecol., 103(2):111-116, 1996.

3403. Sibai, B. and Kupferminc, M., Pre-eclampsia, Lancet, 365:785-799, 2005.

3404. El-Zayat, S.G., Role of phenytoin in the post-convulsion syndrome following missile head injury, J. Neurol. Orthop. Med. Surg., 9(3): 253, 1988.

3405. Lewis, R.J., Yee, L., Inkelis, S.H., and Gilmore, D., Clinical predictors of post-traumatic seizures in children with head trauma, Ann. Emerg. Med., 22(7):1114-1118, 1993.

3406. Haltiner, A.M., Newell, D.W., Temkin, N.R., Dikmen, S.S., and Winn, H.R., Side effects and mortality associated with the use of phenytoin for early posttraumatic seizure prophylaxis, J. Neurosurg., 91:588-592, 1999.

3407. Dikmen, S.S., Temkin, N.R., Miller, B., Machamer, J., Winn, H.R., Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures, JAMA, 265(10): 1271-7, 1991.

3408. Beenen, L.F., Lindeboom, J., Kasteleijn-Nolst Trenite D.G., Heimans, J.J., Snoek, F.J., Touw, D.J., Ader, H.J., and Van Alphen, H.A., Comparative double-blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: Efficacy, tolerability, and cognitive effects, J. Neurol. Neurosurg. Psychiatry, 67:474-480, 1999.

3409. Aldrete, J.A., Romo-Salas, F., and Castillo, R.A., Methods in treating acute cerebral ischemia, Rev. Esp. Anesthesiol. Reanim., 33(3): 193-6, 1986.

3410. Richards, I.M., Fraser, S.M., Hunter, J.A., and Capell, H.A., Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis, Ann. Rheum. Dis., 46(9): 667-9, 1987.

3411. Naidu, M.U., Kumar, T.R., Anuradha, R.T., and Rao, U.R., Evaluation of phenytoin in rheumatoid arthritis - - an open study, Drugs. Exp. Clin. Res., 17(5): 271-5, 1991.

3412. Rao, U.R., Naidu, M.U., Kumar, T.R., Shobha, U., Askar, M.A., Ahmed, N., Sarada, P., Venubabu, K., Shantaram, V., and Menon, G.M., Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis - a double blind study, J. Rheumatol., 22(7): 1235-40, 1995.

3413. Grindulis, K.A., Nichol, F.E., and Oldham, R., Phenytoin in rheumatoid arthritis, Ann. Rheum. Dis., 47(3): 261, 1988.

3414. Wertzberger, P., Phenytoin in the treatment of auricular noise, Rev. Chir. [Otorinolaringol], 33(2): 127-34, 1988.

3415. Tatemoto K., Clinical and electrophysiological investigations of the influence of phenytoin natrium on tinnitus, Nippon Jibiinkoka Gakkai Kaiho, 93(2): 256-7, 1990.

3416. Bernhard, W.N., Martin, K., Mandel, A., Mader, T., Picano, J., and Hiesiger, E., Dilantin and hypoxia of altitude, Presented at the 5th International Hypoxia Symposium, The University of Calgary, McMaster University & The Arctic Institute of North America, 1987.

3417. Picano, J.J., Martin, W.K., Bernhard, W.N., York, D., Mandel, A., Hiesiger, E., and Mohr, L., An experimental model for testing cerebral protective agents for AMS in a hypobaric chamber: The example of phenytoin, Aviat. Space Environ. Med., 59: 482, 1988.

3418. Chelen, W.E., Kabrisky, M., Hatsell, C., Morales, R., Fix, E., and Scott, M., Use of phenytoin in the prevention of motion sickness, Aviat. Space Environ. Med., 61: 1022-5, 1990.

3419. Chelen, W.E., Kabrisky, M., Rogers, S., and Morales, R., Dose/Response of phenytoin in the therapy of motion sickness, Presented at the 61st Annual Scientific Meeting of the Aerospace Medical Association, A59 (Abstr 362), New Orleans, LA, 1990.

3420. Karkishchenko, N.N. and Dimitriadi, N.A., Antiepileptic drugs in the combined medicinal prevention of motion sickness, Kosm. Biol. Aviakosm. Med. (Moscow), 25(1): 21-23, 1991.

3421. Chelen, W.E., Ahmed, N., Kabrisky, M., and Rogers, S., Aviat. Space Environ. Med., 64(3Pt 1): 201-5, 1993.

3422. Woodward, D., Knox, G., Myers, J., Chelen, W.E., and Ferguson, B., Aviat. Space Environ. Med., 64(5) : 363-6, 1993.

3423. Knox, G.W., Woodward, D., Chelen, W.E., Ferguson, R., and Johnson, L., Laryngoscope, 104(8Pt 1): 935-9, 1994.

3424. Stern, R.M., Uijtdehaage, S.H., Muth, E.R., and Koch, K.L., Aviat. Space Environ. Med., 65(6): 518-21, 1994.

3425. Lehr, H.A., Zimmer, J.P., Kern, W., Schoengen, A., Eiermann, T., and Heimpel, H., Aids: Improvement of clinical status and laboratory parameters under diphenylhydantoin therapy, Blut., 53: 1-2, 1986.

3426. Kern, W., Pekar, U., Petzoldt D., Rasche, H., Turowsky-Burwinkel, G.H., Heimpel, H., and Vanek, E., Treatment of symptomatic HIV infection with oral diphenylhydantoin, Aids-Forschung, 6: 334-9, 1989.

3427. Chapa-Alvarez, J.R., Rodriguez-Rivera, A., Valadez-Bautista, C., Rodriguez-Noriega, E., and Parra, G., Results of the use of phenytoin as an aid in preanesthetic mediation for preoperatory anxiety, Invest. Med. Int., 14(3): 155-9, 1987.

3428. Muizelaar, J.P., The use of electroencephalography and brain protection during operation for basilar aneurysms, Neurosurgery, 25(6): 899-903, 1989.

3429. Mizoi, K. and Yoshimoto, T., Permissible temporary occlusion time in aneurysm surgery as evaluated by evoked potential monitoring, Neurosurgery, 33(3):434-40, 1993.

3430. Chebabo, S.R., Do-Carmo, R.J., and Martins-Ferreira, H., The effect of diphenylhydantoin on spreading depression, Braz. J. Med. Biol. Res., 21(3): 603-5, 1988.

3431. Schwarz, J.R. and Grigat, G., Phenytoin and carbamezepine: potential- and frequency dependent block of Na Currents in mammalian myelinated nerve fibers, Epilepsia, 30(3): 286-94, 1989.

3432. Birnstiel, S. and Haas, H.L., Anticonvulsants do not suppress long-term potentiation (LTP) in the rat hippocampus, Neurosci. Lett., 122: 61-63,1991.

3433. Chebabo, S.R. and Do Carmo, R.J., Phenytoin and retinal spreading depression, Brain Res., 551(1-2):16-19, 1991.

3434. Bagri, A., Sandner, G., and Di Scala, G., Wild running and switch-off behavior elicited by electrical stimulation of the inferior Colliculus: effect of anticonvulsant drugs, Pharmacol. Biochem. Behav., 39:683-688, 1992.

3435. Tegtmeier, F., Wilhelm, D., Frankow, C., Thone, F., Vandeplassche, L., and Peters, T., Eeffects of R 56865 and phenytoin on mechanical, biochemical, and morphologic changes during oubain intoxication in isolated perfused rabbit heart, J. Cardiovasc. Pharmacol., 20:421-28, 1992.

3436. Segal, M.M., Phenytoin attenuates seizure-associated plateau bursts in solitary hipocampal neurons, Soc. Neurosci. Abstr., 19 (PT.1): 20, 1993.

3437. Kamei, H., Kameyama, T., and Nabeshima, T., (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated a1 sites, Eur. J. Pharmacol., 309:149-158, 1996.

3438. Lee, G.Y., Brown, L.M., and Teyler, T.J., The effects of anticonvulsant drugs on long-term potentiation (LTP) in the rat hippocampus, Brain Res., Bull., 39(1):39-42, 1996.

3439. Walker, M.C., Alavijeh, M.S., Shorvon, S.D., and Patsalos, P.N., Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex, Epilepsia, 37(5):421-427, 1996.

3440. Rush, A.M. and Elliott, J.R., Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia, Neurosci. Lett., 226:95-98, 1997.

3441. Kang, Y., Okada, T., Ohmori, H., A phenytoin-sensitive cationic current participates in generating the afterdepolarization and burst after discharge in rat neocortical pyramidal cells, Eur. J. Neurosci., 10: 1063-1375, 1998.

3442. Samii, A., Chen, R., Wassermann, E.M., and Hallett, M., Phenytoin does not influence postexercise facilitation of motor evoked potentials, Neurology, 50:291-293, 1998.

3443. Francis, J., Eubanks, J.H., and Mcintyre Burnham, W., Diazepam-potentiated [3H]phenytoin binding is associated with peripheral-type Benzodiazepine receptors and not with voltage-dependent sodium channels, Brain Res., 876:131-140, 2000.

3444. Geary, W.A., Wooten, G.F., Perlin, J.B., and Lothman, E.W., In vitro and in vivo distribution and binding of phenytoin to rat brain, J. Pharmacol. Exp. Ther., 241(2):704-13, 1987.

3445. Sechi, G.P., Russo, A., Rosati, G., Mutani, R., and Monaco, F., Distribution of diphenylhydantoin in the brain during experimental status epilepticus of the cat, Epilepsy Res., 1(3):173-7, 1987.

3446. Netzer, R., Binscheck, T., and Bigalke, H., Phenytoin, baclofen, tizanidine and memantine reduce hyperexcitability of neurons in culture by interfering with different currents, Soc. Neurosci. Abstr., 15: 1301, 1989.

3447. Vivas, L., Chiaraviglio, E., and Carrer, H.F., Rat organum vasculosum laminae terminalis in vitro: responses to changes in sodium concentration, Brain Res., 519: 294-300, 1990.

3448. Leung, L.S. and Shen, B., Long-term potentiation in hippocampal CA1: effects of afterdischarges, NMDA antagonists, and anticonvulsants, Exp. Neurol., 119(2):205-214, 1993.

3449. Buritova, J., Hrabetova, S., Hrabe, J., Mares, P., and Pavlik, V., Influence of carbamezepine and phenytoin on spontaneous activity of cerebellar neurons, Physiol. Res., 43(2):113-6, 1994.

3450. Van den Berg, R.J., Versluys, C.A., De Vosa, A., and Voskuyl, R.A., Nerve fiber size-related block of action currents by phenytoin in mammalian nerve, Epilepsia, 35(6): 1279-88, 1994.

3451. Krsek, P., Haugvicova, R., and Mares, P., Age-dependent phenytoin effects on cortical stimulation in rats, Physiol. Res., 47:143-149, 1998.

3452. Ohno, K. and Higashima, M., Effects of antiepileptic drugs on afterdischarge generation in rat hippocampal slices, Brain Res., 924:39-45, 2002.

3453. De Lorenzo, R.J., Phenytoin - mechanisms of action, in: Antiepileptic Drugs, Third Edition, 143-58, Levy, R., et al, Eds., Raven Press, New York, 1989.

3454. Rho, J.M. and Sankar, R., The pharmacologic basis of antiepileptic drug action, Epilepsia, 40(11):1471-83, 1999.

3455. White, H.S., Comparative anticonvulsant and mechanistic Profile of the established and newer antiepileptic drugs, Epilepsia, 40(5):S2-S10, 1999.

3456. Moshe, S.L., Mechanisms of action of anticonvulsant agents, Neurology, 55(S1):S32-S40, 2000.

3457. Harris, R.A. and Bruno, P., Membrane disordering by anesthetic drugs: relationship to synaptosomal sodium and calcium fluxes, J. Neurochem., 44:1274-81, 1985.

3458. Willow, M., Gonoi, T., Postma, S.W., and Catterall, W.A., Inhibition of voltage-sensitive sodium channels by local anesthetics and anticonvulsants, Molecular and Cellular Mechanisms of Anesthetics, a Biochemical and Physiological Analysis, 243-58, Roth, S.H. and Miller, K.W., Eds., Plenum Press, New York, 1986.

3459. Schauf, C.L., Anticonvulsants modify inactivation but not activation processes of sodium channels in myxicola axons, Can. J. Pjysiol. Pharmacol., 65:1220-5, 1987.

3460. Quandt, F.N., Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells, Mol. Pharmacol., 34(4): 557-66, 1988.

3461. Schwartz, J.R., Membrane currents and action potentials of myelinated nerve fibers and their modification by diphenylhydantoin and tocainide, EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb., 9(3):115-22, 1988.

3462. Tomaselli, G.F., Marban, E., Yellen, G., Sodium channels from human brain RNA expressed in xenopus oocytes. Basic electrophysiologic characteristics and their modification by diphenylhydantoin, J. Clin. Invest., 83: 1724-32,1989.

3463. Barber, M.J., Starmer, C.F., and Grant, A.O., Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin, Circ. Res., 69: 677-96, 1991.

3464. Ragsdale, D.S., Scheuer, T., Catterall, W.A., Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs, Mol. Pharmacol., 40(5): 756-65, 1991.

3465. Francis, J., Burnham, W.M., [3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels, Mol. Pharmacol., 42(6): 1097-1103, 1992.

3466. Kuo, C.C., Bean, B.P., Fast and slow Na channel inactivation and the action of phenytoin in rat hippocampal neurons, Soc. Neurosci. Abstr., 19(2): 1630, 1993.

3467. Kuo, C.C., Bean, B.P., Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons, Mol. Pharmacol., 46(4): 716-25, 1994.

3468. Segal, M.M., Zurakowski, D., Douglas, A.F., Late sodium channel openings underlie ictal epileptiform activity, and are preferentially diminished by the anticonvulsant phenytoin, Soc. Neurosci. Abstr., 21(PT.1):777, 1995.

3469. Ragsdale, D.S., McPhee, J.C., Scheuer, T., Catterall, W.A., Common molecular determinants of local anesthetic antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels, Proc. Natl. Acad, Sci., USA, 93(17): 9270-5, 1996.

3470. Song, J.H., Nagata, K., Huang, C.S., Yeh, J.Z., Narahashi, T., Differential block of two types of sodium channels by anticonvulsants, Neuroreport, 7: 3031-3036, 1996.

3471. Kuo, C.C., Chen, R.S., Lu, L., Chen, R.C., Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications, Mol. Pharmacol., 51:1077-1083, 1997.

3472. Segal, M.M., Douglas, A.F., Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin, J. Neurophysiol., 77(6): 3021-34, 1997.

3473. Kuo, C.C., A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels, Mol. Pharmacol., 54: 712-721, 1998.

3474. Lampl, I., Schwindt, P., Crill, W., Reduction of cortical pyramidal neuron excitability by the action of phenytoin on persistent Na+ current, J. Pharm. Exp.Ther., 284(1): 228-237, 1998.

3475. Nobile, M., Lagostena, L. A discriminant block among K+ channel types by phenytoin in neuroblastoma cells, Br. J. Pharmacol., 124: 1698-1702, 1998.

3476. Pugsley, M.K., Yu, E.J., McLean, T.H., Goldin, A.L., Blockade of neuronal sodium channels by the antiepileptic drugs phenytoin, carbamazepine and sodium valproate, Proc. West. Pharmacol. Soc., 42:105-108, 1999.

3477. Brumberg, J.C., Nowak, L.G., McCormick, D.A., Ionic mechanisms underlying repetitive high-frequency burst firing in supragranular cortical neurons, J. Neurosci., 20(13): 4829-43, 2000.

3478. Rolf, S., Haverkamp, W., Borggrefe, M., Muboff, U., Eckardt, L., Mergenthaler, J., Snyders, D.J., Pongs, O., Speckmann, E.J., Breithardt, G., Madeja, M., Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes, Naunyn Schmiedebergs Arch. Pharmacol., 361(1): 22-31, 2000.

3479. Catterall, W.A., Common modes of drug action on Na+ channels: local anesthetics, antiarrhythmics and anticonvulsants, Trends Pharmacol. Sci., 8: 57-65, 1987.

3480. Worley, P.F., Baraban, J.M., Site of anticonvulsant action on sodium channels: autoradiographic and electrophysiological studies in rat brain, Proc. Natl. Acad. Sci. USA, 84: 3051-5, 1987.

3481. Cunningham, M.O., Jones, R.S.G., Dendrotoxin sensitive potassium channels modulate GABA but not glutamate release in the rat entorhinal cortex in vitro, Neuroscience, 107(3): 395-404, 2001

3482. Su, H., Alroy, G., Kirson, E.D., Yaari, Y., Extracellular calcium modulates persistent sodium current-dependent burst-firing in hippocampal pyramidal neurons, J. Neurosci., 21(12):4173-82, 2001.

3483. Jeub, M., Beck, H., Siep, E., Ruschenschmidt, C., Speckmann, E.J., Ebert, U., Potschka, H., Freichel, C., Reissmuller, E., Loscher, W., Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats, Neurophamacology, 42: 107-116, 2002.

3484. Rivet, M., Bois, P., Cognard, C., and Raymond, G., Phenytoin preferentially inhibits L-type calcium currents in whole-cell patch-clamped cardiac and skeletal muscle cells, Cell Calcium, 11: 581-588, 1980.

3485. Twombly, D.A., Yoshi, M., Narahashi, T., Mechanisms of calcium channel block by phenytoin, J. Pharamol. Exp.Ther., 246(1): 189-95, 1988.

3486. Miyazaki, .T, Hashiguchi, T., Hashiguchi M., Sakai S., Tosaka T., Kanazawa, M., Phenytoin partially antagonized L-type Ca2+ current in glucagons-secreting tumor cells (ITC-1), Naunyn Schmiedebergs Arch. Pharmacol., 345: 78-84, 1992.

3487.Takahashi, K., Kameda, H, Kataoka, M., Ueno, S., and Akaike, N., Effects of Ca2+ Antagonists and antiepileptics on tetrodotoxin-sensitive Ca2+-conducting channels in isolated rat hippocampal Ca1 neurons, Neurosci. Lett., 148(1-2): 60-62, 1992.

3488. Kobrinsky, E.M., Pearson, H.A., and Dolphin, A.C., Low- and high-voltage-activated calcium channel currents and their modulation in the dorsal root ganglion cell line ND7-23, Neuroscience, 58(3):539-52, 1994.

3489. Schumacher, T.B., Beck, H., Steinhauser, C., Schramm, J., and Elger, C.E., Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy, Epilepsia, 39(4):355-363, 1998.

3490. Rampe, D., Ferrante, J., and Triggle, D.J., The actions of diazepam and diphenylhydantoin on fast and slow Ca2+ uptake processes in guinea pig cerebral cortex synaptosomes, Can. J. Physiol. Pharmacol., 65(4):538-43,1987.

3491. Sugaya, E., Onozuka, M., Furuichi, H., Kishii, K., Imai, S., and Sugaya, A., Phenytoin effects on pentylenetetrazole-indiced intracellular calcium related abnormal phenomena, Advances in Epileptology, 507-10, Vol 16, Wolf, P., et al, Eds., Raven Press, New York, 1987.

3492. White, H.S., Skeen, G.A., and Edwards, J.A., Pharmacological regulation of astrocytic calcium channels: implications for the treatment of seizure disorders, Prog. Brain Res.,, 94: 77-87, 1992.

3493. Sayer, R.J., Brown, A.M., Schwindt, P.C., and Crill, W.E., Calcium currents in acutely isolated human neocortical neurons, J. Neurophysiol., 69(5):1596-1606, 1993.

3494. Dreier, J.P., Zhang, C.L., and Heinemann, U., Phenytoin, Phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but you can prevent its development, Acta. Neurol. Scand., 98:154-160, 1998.

3495. Pincus, J.H. and Kiss, A., Phenytoin reduces early acetylcholine release after depolarization, Brain Res.,, 397: 103-7, 1986.

3496. Pincus, J.H. and Kiss, A., Phenytoin, tetrodotoxin, and acetylcholine release, Exp. Neurol., 94: 777-81, 1986.

3497. Diamond, B.I. and Nguyen, T.H., Effect of seizures and diphenylhydantoin on MPTP toxicity, Neurology, 38(SUP 1): 332, 1988

3498. Markianos, M. and Kalfakis, N., Neurotransmitter metabolites in medicated epileptic patients, Funct. Neurol., 6(4): 367-370, 1991.

3499. Wong, P.T. and Teo, W.L., The effect of phenytoin on glutamate and GABA transport, Neurochem. Res., 11(9): 1379-82, 1986.

3500. Kaneko, S., Hirano, T., Kondo, T., Otani, K., Fukushima, Y., Hishida, R., Matsunaga, M., Antiepileptic drug phenytoin potentiates GABA in the rat cuneate nucleus, Jpn. J. Psych. Neurol., 42(3): 643-45, 1988.

3501. Ruiz, G., Hamon, M., and Verge, D., Chronic phenytoin treatment decreases GABA, but not betaadrenoceptors in the cerebellum of young rats, Eur. J. Pharmacol.,168: 251-5, 1989.

3502. Swaiman, K.F. and Machen, V.L., Effects of Phenobarbital and phenytoin on cortical glial cells in culture, Brain Dev., 13: 242-6, 1991.

3503. Kapetanovic, .I.M, Yonekawa, W.D., Kupferberg, H.J., The effects of phenytoin (PHT) on 4-aminopyridine (4AP)-induced changes in neurotransmitter amino acids (AA) in rat hippocampus in vitro, Soc. Neurosci. Abstr., 18: 379, 1992.

3504. Zhang, H., Hu, Y., He, S., In vitro study: the mechanisms of antiepileptic drugs on experimental epilepsy, Epilepsia, 42(S7): 231-232, 2001.

3505. Wamil, A.W. and McLean, M.J., Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons, J. Pharmacol. Exp. Ther., 267(1): 218-27, 1993.

3506. Fraser, C.M., Sills, G.J., Forrest, G., Thompson, G.G., and Brodie, M.J., Effects of anti-epileptic drugs on glutamate synthetase activity in mouse brain, Br. J. Pharmacol., 126:1634-1638, 1999.

3507. Lingamaneni, R. and Hemmings, H.C. Jr, Effects of anticonvulsants on vertridine- and KCL-evoked glutamate release from rat cortical synaptosomes, Neurosci. Lett., 276: 1270130, 1999.

3508. Cunningham, M.O., Dhillon, A., Wood, J., and Jones, R.S.G., Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin, Neuroscience, 95(2): 343-351, 2000.

3509. Koh, J.Y. and Choi, D.W., Effect of anticonvulsant drugs on glutamate neurotoxicity in cortical cell culture, Neurology, 37: 319-22, 1987.

3510. Kawano, H., Sashihara, S., Mita, T., Ohno, K., Kawamura, M., and Yoshii, K., Phenytoin, an antiepileptic drug, competitively blocked non-NMDA receptors produced by xenopus oocytes, Neurosci. Lett., 166(2):183-86, 1994.

3511. Petroff, O.A.C., Rothman, D.L., Behar, K.L., Hyder, F., and Mattson, R.H., Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures, Seizure, 8:120-127, 1999.

3512. Churchill, J.D., Green, J.T., Voss, S.E., Manley, E., Steinmetz, J.E., and Garraghty, P.E., Discrimination reversal conditioning of an eyeblink response is impaired by NMDA receptor blockade, Integr. Physiol. Behav. Sci., 36(1): 62-74, 2001.

3513. Richardson, S.B. and Twente, S., Anticonvulsants inhibit rat neuronal somatostatin release, Brain Res.,, 571(2):230-234, 1992.

3514. Khalid, K., Koller, W., Reigemball, K., Swiergosz, M., Bohn, R., and Nadi, N.S., The effects of valproic acid, carbamazepine and phenytoin on the levels of neuropeptide Y in five brain regions, Soc. Neurosci. Abstr., 26(PT1): 272.3, 2000.

3515. Lahtinen, H., Pitkanen, A., Tuomisto, L., and Riekkinen, P., Effect of antiepileptic drugs on somatostatin release in vitro, Neuropeptides, 17: 29-34, 1990.

3516. Theodore, W.H., Antiepileptic drugs and cerebral glucose metabolism, Epilepsia, 29(S2): S48-55, 1988.

3517. Krenz, N.R., Cooper, R.M., A combined cobalt and C-14 2-deoxyglucose approach to antiepileptic drug assessment, Int. J. Neurosci., 86(1-2):55-66, 1996.

3518. Shimada, S., Kaneko, S., Kondo, T., Hirano, T., Otani, K., and Fukushima, Y., TRH test with analysis of TSH, prolactin and GH responses in patients with phenytoin, carbamazepine or diazepam, Jpn. J. Psychiatry Neurol., 41(3): 521-3, 1987.

3519. Melisi, J.W., Dow-Edwards, D.L., Hammock, K.M., and Milhorat, T.H., Effects of chronic diphenylhydantoin on cerebral metabolism in the adult rat, Exp. Neurol., 99(3): 523-30, 1988.

3520. Tsagarakis S., Rees, L.H., Besser, G.M., and Grossman, A., Involvement of calmodulin in depolarization-induced release of corticotrophin-releasing hormone-41 from the rat hypothalamus in vitro, J. Mol. Endocrinol., 7: 71-75, 1991.

3521. Lim, C.F., Loidi, N.M., Kennedy, J.A., Topliss, D.J., and Stockigt, J.R., Effect of loop diuretics and nonsteroidal anti-inflammatory drugs on thyrothrpin release by rat anterior pituitary cells in vitro, Metabolism, 44(8): 1008-12, 1995.

3522. Lim, C.F., Loidl, N.M., Kennedy, J.A., Topliss, D.J., and Stockigt, J.R., Drug effects on triiodothyronine uptake by rat anterior pituitary cells in vitro, Exp. Clin. Endocrinol. Diabetes, 104(2):151-7, 1996.

3523. Cooper, C.W., Yi, S.J., and Seitz, P.K., Inhibition by phenytoin of in vitro secretion of calcitonin from rat thyroid glands and cultured rat c-cells, J. Bone Mineral Res., 3(2): 219-23, 1988.

3524. Seitz, P.K. and Cooper, C.W., Cosecretion of calcitonin and calcitonin gene-related peptide from cultured rat medullary thyroid c cells, J. Bone Mineral. Res., 4(1): 129-134, 1989.

3525. Cadnapaphornchai, P., Kellner, D., and McDonald, F.D., Role of adrenoreceptors in diphenylhydantoin-stimulated rennin release, Proc. Soc. Exp. Biol. Med., 190(4): 344-8, 1989.

3526. Jaworska-Feil, L., Budziszewska, B., Leskiewicz, M., and Lason, W., Effects of some centrally active drugs on the allopregnanolone synthesis in rat brain, Pol. J. Pharmacol., 52: 359-365, 2000.

3527. Hass, W.K. and Alps, B.J., Protection against acute ischemic changes in a new rat 4 vessel occlusion model with high dose nicardipine and phenytoin, Acute Brain Ischemia, Serono Symposium Publications, Vol 32: 253-6, Battistini, N., et al., Eds., Raven Press, New York, 1986.

3528. Shiu, G.K., Nemoto, E.M., and Nemmer, J., Dose of thiopental, pentobarbital, and phenytoin for maximal therapeutic effects in cerebral ischemic anoxia, Crit. Care Med., 11(6):452-59, 1983.

3529. Abe, K. and Kogure, K., Prevention of an increase in susceptibility to calcium in a neuroblastoma cell line, Neurosci. Lett., 80: 327-32, 1987.

3530. De Lorenzo, R.J., Taft, W.C., and Clifton, G.L., Phenytoin protects against ischemia-induced neuronal damage, Neurology, 37(SUP1): 249, 1987.

3531. Gueldry, S., Rochette, L., and Bralet, J., Comparison of the effects of valproate, ethosuximide, phentoin, and pentobarbital on cerebral energy metabolism in the rat, Epilepsia, 28(2): 160-8, 1987.

3532. King, G.A., Protection against hypoxia-induced lethality in mice: a comparison of the effects of hypothermia and drugs, Arch. Int. Pharmacodyn.Ther., 286: 282-98, 1987.

3533. Suzuki, J., Abiko, H., Mizoi, K., Oba, M., and Yoshimoto, T., Protective effect of phenytoin and its enhanced action by combined administration with mannitol and vitamin E in cerebral ischemia, Acta. Neurochir. (Wien), 88:56-64,1987.

3534. Draguzya, M.D. and Lustin, S.I., Effect of diphenine on animal tolerance to acute hypoxic hypoxia, Kosm. Biol. Aviakosm. Med. (Moscow), 22(3): 92-4, 1988.

3535. Fukuda, A., Akagi, K., Masuda, Y., and Zushi, K., Combination effects of phenytoin (PHT) and prostaglandin (Ip2) (PGI2) on gasping movement by decapitation in mice, Med. Biol.,117(2): 149-52, 1988.

3536. Fukuda, A., Akagi, K., Masuda, Y., and Zushi, K., Protective effect of anticonvulsant drugs against cerebral hypoxia in mice, Igaku. No. Ayumi., 144(12): 917-8,1988.

3537. Imaizumi, S., Kinouchi, H., Tominaga, T., Yoshimoto, T., and Suzuki, J., Biochemical events in the ischemic brain and pharmacological basis of mannitol, vitamin E, glucocorticoid, and phenytoin, Advances in Surgery for Cerebral Stroke, 257-63, Suzuki, J., Ed., Springer-Verlag, Tokyo, 1988.

3538. Imaizumi, S., Suzuki, J., Kinouchi, H., and Yoshimoto, T., Superior protective effects of phenytoin against hypoxia in a pharmacological screening test, Neurol. Res., 10: 18-24, 1988.

3539. Kinouchi, H., Imaizumi, S., Suzuki, J., Yoshimoto, T., and Motomiya, M., The effect of phenytoin on free fatty acid liberation and mononucleotide metabolism in transient ischemia, No. To. Sjinkei., 40(11): 1059-65, 1988.

3540. Clifton, G.L., Taft, W.C., Blair, R.E., Choi, S.C., and De Lorenzo, R.J., Conditions for pharmacologic evaluation in the gerbil model of forebrain ischemia, Stroke, 20: 1545-1552, 1989.

3541. Fukuda, A., Akagi, K., Masuda, Y., and Zushi, K., Protective effects of anticonvulsant drugs against experimental head injury in mice, Med. Biol., 118(6): 369-71, 1989.

3542. Koida, M., Nakamuta, H., Yasuda, K., Muguruma, K., Hiramatsu, Y., Ogawa, Y., and Kato, Y., Carbon monoxide (CO)-induced hypoxia in mice: evaluation as an experimental model of cerebral ischemia for drug screening, Jpn. J. Pharmacol., 51: 273-278, 1989.

3543. Kurosawa, K., Imaizumi, S., Kinouchi, H., Yoshimoto, T., and Suzuki, J., A study on the protective mechanism of phenytoin in transient global ischemia, Brain and Nerve, 17: 427-34, 1989.

3544. Yang, C., Schwartz, P.H., Hattori, H., Fijikawa, D.G., Morin, A.M., and Wasterlain, C.G., The combination of dextromethorphan and phenytoin has potent anti-ischemic properties, Soc. Neurosci. Abstr., 15: 43, 1989.

3545. Boxer, P.A., Cordon, J.J., Mann, M.E., Rodolosi, L.C., Vartanian, M.G., Rock, D.M., Taylor, C.P., and Marcoux, F.W., Comparison of phenytoin with noncompetitive N-Mmethyl-D-Aaspartate antagonists in a model of focal brain ischemia in rat, Stroke, 21: III47-III51, 1990.

3546. Kinouchi, H., Imaizumi, S., Yoshimoto, T., and Motomiya, M., Phenytoin affects metabolism of free fatty acids and nucleotides in rat cerebral ischemia, Stroke, 21(9): 1326-32, 1990.

3547. Lantos, J., Sarosi, I., Temes, G., and Torok, B., Influence of protective drugs on the EEG during short-term transient ischaemia, Acta. Physiol. Hung., 75(3): 217-27, 1990.

3548. Lantos, J., Temes, G., Kelemen, D., Sarosi, I, and Torok, B., Influence of protective drugs on the elevation of extracellular potassium ion concentration in the brain during ischaemia, Acta. Physiol. Hung., 76(1): 49-59, 1990.

3549. Potter P.E., Eeffects of phenytoin and hypoxia on acetylcholine release, Personal Communication, 1990.

3550. Sarmiento, J.G., Childs, C.A., Dent, G.W., and Buyniski, J.P., Alteration of elevated Ca2+ content in occluded gerbil hippocampus by MK-801, phenytoin, and nicardipine, FASEB J., 4(3): A400, 1990.

3551. Schanne, F.A. and Moskal, J.R., 31P NMR study of ischemia in NG108-15 cells:effects of phenytoin and magnesium on recovery of high energy phosphates, Personal Communication, 1990.

3552. Schanne, F.A., Stanton, P.K., Smith, B.H., and Moskal, J.R., 31P-NMR studies of ischemia in NG108-15 cells: Effects of phenytoin and MG 2+ on recovery of high energy phosphates, Soc. Neurosci. Abstr., 16: 936, 1990.

3553. Cordon, J.J., Boxer, P.A., and Marcoux, F.W., The effects of fosphenytoin on infarct size and behavioral deficits in rat models of focal ischemia, Soc. Neurosci. Abstr., 17(PT.2): 1078, 1991.

3554. Potter, P.E., Detwiler, P., Thorne, B., and Moskal, J.R., Diphenyhydantoin attenuates hypoxia-induced release of 3H-glutamate from rat hippocampal slices, Brain Res.,, 558(1): 127-130, 1991.

3555. Stanton, P.K. and Moskal, J.R., Diphenylhydantoin protects against hypoxia-induced impairment of hippocampal synaptic transmission, Brain Res.,, 546(2): 351-54, 1991.

3556. Boehm, F.H., Moskal, J.R., and Liem, L.K., Phenytoin increases the survival of cultured hippocampal neurons subjected to hypoxia, Personal Communication, 1992.

3557. Mehler, M.F., Haas, K.Z., Kessler, J.A., and Stanton, P.K., Enhanced sensitivity of hippocampal pyramidal neurons from MDX mice to hypoxia-induced loss of synaptic transmission, Proc. Natl. Acad. Sci. USA, 89(6):2461-65, 1992.

3558. Qi, L., Protective action of phenytoin on cerebral ischemia in rats, Chin. Med. J., 72(7): 424-27, 1992.

3559. Fern, R., Ransom, B.R., Stys, P.K., and Waxman, S.G., Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamezepine and diazepam, J. Pharmacol. Exp. Ther., 266(3): 1549-55, 1993.

3560. Grundmann, K., Qi, H., Hospod, F.E., and Newman, G.C., Protective effects of phenytoin and pentobarbital in ischemic thick brain slices, Personal Communication, 1993.

3561. Boehm, F.H., Liem, L.K., Stanton, P.K., Potter, P.E., and Moskal, J.R., Phenytoin protects against hypoxia-induced death of cultured hippocampal neurons, Neurosci. Lett., 175(1-2):171-4, 1994.

3562. Hayakawa, T., Hamada, Y., Maihara, T., Hattori, H., and Mikawa, H., Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats, Life Sci., 54(6):387-92, 1994.

3563. Rataud, J., Debarnot, F., Mary, V., Pratt, J., and Stutzmann, J.M., Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia an electric convulsions in rodents, Neurosci. Lett., 172(1-2):19-23, 1994.

3564. Weber, M.L. and Taylor, C.P., Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials, Brain Res.,, 664:167-177, 1994.

3565. Imaizumi, S., Kurosawa, K., Kinouchi, H., and Yoshimoto, T., Effect of phenytoin on cortical Na+ K+ -ATPase activity in global ischemic rat brain, J. Neurotrauma, 12(2):231-4, 1995.

3566. Lampley, E.C., Mishra, O.P., Graham, G., and Delivoria-Papadopoulos, M., Neuroprotective effect of phenytoin against in utero hypoxic brain injury in fetal guinea pigs, Neurosci. Lett., 186(2-3):192-6, 1995.

3567. Lynch, III J.J., Yu, S.P., Canzoniero, L.M., Ssensi, S.L., and Choi, D.W, Sddium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists, J. Pharmacol. Exp. Ther., 273(1):554-60, 1995.

3568. Mark, R.J., Ashford, J.W., Goodman, Y., and Mattson, P.M., Anticonvulsants attenuate amyloid -peptide neurotoxicity, Ca2+ deregulation and cytoskeletal pathology, Neurobiol. Aging, 16(2):187-98, 1995.

3569. Martos, A., Cabellos, C., Martinez-Lacasa, J., Viladrich, P.F., and Gudiol, F., Protective effect of dexamethasone and phenytoin in the treatment of experimental pneumococcal meningitis, Enferm. Infec. Microbiol. Clin.,13(3):146-50, 1995.

3570. Taylor, C.P., Probert, A.W., and Marcoux, F.W., Tetrodotoxin and phenytoin delay death from oxygen and glucose deprivation in rat neocortical cultures, Soc. Neurosci. Abstr., 21(PT.1):218, 1995.

3571. Watson, G.B. and Lanthorn, T.H., Phenytoin delays ischemic depolarization, but cannot block its long-term consequences, in the rat hippocampal slice, Neuropharmacology, 34(5):553-58, 1995.

3572. Zhang, Y. and Dong, W., Protective effects of phenytoin on glutamate neurotoxicity in cultured neurons, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1995.

3573. Bausch, A.R. and Roy, G., Volume-sensitive chloride channels blocked by neuroprotective drugs in human glial cells (U-138MG), Gut., 18:73-77, 1996.

3574. Qi, H. and Newman, G.C., Phenytoin-induced hyperglycemia may confound rat cerebroprotection models, Clin. Exp. Pharmacol. Physiol., 23:893-897, 1996.

3575. Vartanian, M.G., Cordon, J.J., Kupina, N.C., Schielke, G.P., Posner, A., Raser, K.J., Wang, K.K.W. and Taylor, C.P., Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats, Dev. Brain Res.,, 95:169-175, 1996.

3576. Probert, A.W., Borosky, S., Marcoux, F.W., and Taylor, C.P., Sodium channel modulators prevent oxygen and glucose deprivation injury and glutamate release in rat cortical cultures, Neuropharmacology, 36(8):1031-1038, 1997.

3577. Chan, S.A., Reid, K.H., Schurr, A., Miller, J.J., Tseng, M.T., Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia, Acat. Neurochir. (Wien), 140: 175-180, 1998.

3578. Frantseva, M.V., Carlen, P.L., and El-Beheiry, H., A submersion method to induce hypoxic damage in organotypic hippocampal cultures, J. Neurosci. Methods, 89: 25-31, 1999.

3579. Herguido, M.J., Carceller, F., Roda, J.M., and Avendano, C., Hippocampal cell loss in transient global cerebral ischemia in rats: a critical assessment, Neuroscience, 93(1):71-80, 1999.

3580. King, G.A. and Narcavage, D., Comparison of the effects of vinpocetine, vincamine, phenytoin, and cinnarizine in a rat model of cerebral ischemia, Drug Dev. Res., 9: 225-31, 1986.

3581. Deshpande, J.K., Traystman, R.J., and Wieloch, T., Phenytoin therapy does not improve postischemic brain damage, Faseb J. , 2(5):A1290, 1988.

3582. Cordon, J.J., Boxer, P.A., and Marcoux, F.W., Phenytoin decreases the volume of ischemic damage caused by middle cerebral artery occlusion in F-344 rats, Soc. Neurosci. Abstr. , 14(PT 2): 816, 1988.

3583. Rolfsen, M.L. and Davis, W.R., Cerebral function and preservation during cardiac arrest, Crit. Care Med. , 17(3): 283-92, 1989.

3584. Fukuda, A., Akagi, K., Masuda, Y., and Zushi, K., Protective effects of anticonvulsant drugs against complete cerebral ischemia in mice, Igaku. To. Seibutsugaku. , 118: 85-7, 1989.

3585. McNally, W.P., De Hart, P., Cordon, J.J., Rock, D.M., and Taylor, C.P., Distribution of 14C-phenytoin in rat brain following middle cerebral artery occlusion (MCAO), Soc. Neurosci. Abstr. , 385.

20, 1990.

3586. Vartanian, M.G., Cordon, J.J., Kupina, N.C., Schielke, J., and Taylor, C.P., Phenytoin and CI 953 attenuate hypoxic-ischemic brain damage in neonatal rats, Soc. Eurosci. Abstr. , 19(PT.2):1657, 1993.

3587. Fisher, M., Neuroprotection of acute ischemic stroke: where are we now?, Neuroscientist, 5(6):392-401, 1999.

3588. De Keyser, J., Sulter, G., and Luiten, P.G., Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right?, Trends Neurosci. , 22(12):535-540, 1999.

3589. Calabresi, P., Picconi, B., Saulle, E., Centonze, D., Hainsworth, A.H., and Bernardi, G., Is pharmacological neuroprotection dependent on reduced glutamate release?, Stroke, 31:766-773, 2000.

3590. Pulsinelli, W.A., Mann, M.E., Welch, M.A., Zivin, J.A., Biller, J., Maisel, J., Rubin, J.J., Verro, P., Graham, G.D., Pierce, M., et al., Fosphenytoin in acute ischemic stroke: efficacy results, Neurology, 52(2): A384, 1999.

3591. Flick, M.R., Webster, R.O., Hoeffel, J.M., Julien, M., Milligan, S.A., Kent, B., and Lesser, M., Effect of phenytoin on acute lung injuries in unanesthetized sheep, Crit. Care Med. , 21(10):1562-71, 1993.

3592. Nasker, R., Schuettauf, F., Quinto, K., and Dreyer, E., Phenytoin blocks retinal ganglion cell death after partial optic nerve crush, Soc. Neurosci. Abstr. , 26(PT1): 29.15, 2000.

3593. Imaizumi, T., Kocsis, J.D., and Waxman, S.G., Anoxic injury in the rat spinal cord: pharmacological evidence for multiple steps in Ca+2 -dependent injury of the dorsal columns, J. Neurotrauma, 14(5): 299-311, 1997.

3594. Gangemi, J.J., Kern, J.A., Ross, S.D., Shockey, K.S., Kron, .I.L, and Tribble, C.G., Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection, Ann. Thorac. Surg. , 69: 1744-9, 2000.

3595. Watanabe, Y., Gould, E., Cameron, H.A., Daniels, D.C., McEwen, B.S., Phenytoin prevents stress- and corticosterone-indiced atrophy of CA3 pyramidal neurons, Hippocampus, 2(4): 431-435, 1992.

3596. Luine, V., Villegas, M., Martinez, C., Mcewen, B.S., Repeated stress causes reversible impairments of spatial memory performance, Brain Res., , 639(1):167-70, 1994.

3597. Magarinos, A.M. and McEwen, B.S., Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of excitatory amino acid receptors, Neuroscience, 69(1):89-98, 1995.

3598. Kamei, H., Kameyama, T., and Nabeshima, T., (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated s 1 sites, Eur. J. Pharmacol. , 299:21-28, 1996.

3599. Magarinos, A.M., McEwen, B.S., Flugge, G., and Fuchs, E., Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews, J. Neurosci. , 16(10):3534-40, 1996.

3600. Kamei, H., Kameyama, T. Nabeshima, T., Effects of s receptor ligands on conditioned fear stress, Methods Find. Exp. Clin. Pharmacol. , 20(7): 613-618, 1998.

3601. Reagan, L.P., McKittrick, C.R., and McEwen, B.S., Corticosterone and phenytoin reduce neuronal nitric oxide synthase messenger RNA expression in rat hippocampus, Neuroscience, 91(1): 211-219, 1999.

3602. McEwen, B.S., Albeck, D., Cameron, H., Chao, H.M., Gould, E., Hastings, N., Kuroda Y.,Luine, V., Magarinos, A.M., and McKittrick, C.R., Stress and the brain: a paradoxical role for adrenal steroids, in: Vitamins and Hormones, Litwack, G.D., ed, Academic Press, Orlando, 51:371-402, 1995.

3603. Al-Solaiman, A. and Iyer, V., The effects of diphenylhydantoin on myotonia induced in skeletal muscle by 2,4-D: in vitro study, Neurology, 38(Sup 1): 187, 1988.

3604. Beech, J., Fletcher, J.E., Lizzo, F., and Johnston, J., Effect of phenytoin on the clinical signs and in vitro muscle twitch characteristics in horses with chronic intermittent rhabdomyolysis and myotonia, Am. J. Vet. Res., 49(12): 2130-3, 1988.

3605. Duruibe, V.A. and Blyden, G.T., Direct modulation of creatine kinase activity by diphenylhydantoin, Faseb J., 3(4): A1184, 1989.

3606. Raines, A., Henderson, T.R., and Dretchen, K.L., Effects of calcium channel blocking agents on neostigmine-induced fasciculations, Eur. J. Pharmacol., 173:11-17,1989.

3607. Huntington, P.J., Seneque, S., Slocombe, R.Ff, Jeffcott, L.B., McLean, A., Luff, A.R., Use of phenytoin to treat horses with Australian stringhalt, Aust. Vet. J., 68: 221-224, 1991.

3608. Roed, A., Selective potentiation of subtetanic and titanic constrictions by the calcium-channel antogonist nifedipine in the rat diaphragm preparation, Gen. Pharmacol., 22(2): 313-318, 1991.

3609. Beech, J., Fletcher, J.E., Tripolitis, L., and Lindborg, S., Effects of phenytoin in two myotonic horses with hyperkelamic periodic paralysis, Muscle Nerve,15(8): 932-936, 1992.

3610. Mehler, M.F., Haas, K.Z., Kessler, J.A., and Stanton, P.K., Enhanced sensitivity of hippocampal pyramidal neurons from MDX mice to hypoxia-induced loss of synaptic transmission, Proc. Natl. Acad. Sci. USA, 89(6):2461-65, 1992.

3611. Fletcher, J.E., Erwin, K., and Beech, J., Phenytoin increases specific triacylglycerol fatty esters in skeletal muscle from horses with hyperkalemic periodic paralysis, Biochim. Biophys. Acta, 1168(3): 292-8, 1993.

3612. Beech, J., Fletcher, J.E., Tripolitis, L., Lindborg, S., and Dawso, T., Effect of phenytoin on skeletal muscle from quarter horses with hyperkalemic paeriodic paralysis, Res. Vet. Sci., 58(3):206-11, 1995.

3613. Yudowsky, M.L., Beech, J., and Fletcher, J.E., Phenytoin alters transcript levels of hormone-sensitive lipase in muscle from horses with hyperkalemic periodic paralysis, Arch. Biochem. Biophys., 358(2): 264-270, 1998.

3614. Strasburger, J.F., Duncan, J.M., Frazier, O.H., Garson, A., and Moak, J.P., Cellular electrophysiologic effects of phenytoin in human myocardium differ from reported animal data, Pace, 10: 431(ABS 99), 1987.

3615. Wagner, B., Strumpf, G., and Bartoszyk, G.D., Similar effects of ralitoline and phenytoin on papillary muscle action potentials: evidence for sodium antagonistic activity, Pharmacol. Res. Commun., 19(9): 591-6, 1987.

3616. Xie, H. and Wang, G.X., Effects of combination of diphenylhydantoin and prostaglandin E2 on oubain-induced arrhythmias, Acta. Pharmaceutica Sinica, 23(12): 953-955, 1988.

3617. Damarowsky and M., Lullmann, H., A model to check the arrhythmogenic activity of antiarrhythmic drugs, Gen. Pharmacol., 22(3): 533-37, 1991.

3618. Hayashi, Y., Kamibayashi, T., Sumikawa K., Yamatodani, A., Kuro, M., and Yoshiya, I., Phenytoin prevents epinephrine-induced arrhythmias through central nervous system in halothane-anesthesized dogs, Res. Commun. Chem. Pathol. Pharmacol., 74(1): 59-70, 1991.

3619. Kaschube, M. and Brasch, H., Negative chronotropic but no antiarrhythmic effect of (+)-and (-)-naloxone in rats and guinea pigs, Cardiovasc. Res., 25: 230-234, 1991.

3620. Dzimiri, N., Effects of procainamide, tocainide and phenytoin on guinea pig cardiac mitochondrial ATPase activity, Res. Commun. Chem. Pathol. Pharmacol., 80(1): 121-4, 1993.

3621. Simaan, J.A., Influence of pretreatment with phenytoin, lidocaine and quinidine on the cardiodynamic on the cardiodynamic and electrophysiological effects of oubain in the cat heart-lung preparation, Arch. Int. Pharmacodyn., 324:47-59, 1993.

3622. Ishide, N., Intracellular calcium modulators for cardiac muscle in pathological conditions, Jpn. Heart J., 37(1):1-17, 1996.

3623. Ciechanowicz-Rutkowska, M., Stadnicka, K., Kiec-Kononowicz, K.K., Byrtus, H., Filipek, B., Zygmunt, M., and Maciag, D., Structure-activity relationship of some new anti-arrhythmic phenytoin derivatives, Arch. Pharm. (Wienheim), 333:357-364, 2000.

3624. Peon, J., Ferrier, G.R., and Moe, G.K., The relationship of excitability to conduction velocity in canine purkinje tissue, Circ. Res., 43(1): 125-35, 1978.

3625. Liao, K., Seifter, E., Factor, S.M., Yellin, E.L., and Frater, R.W., Diphenylhydantoin inhibits calcification of bovine pericardial implants and myocardium a preliminary study, J. Surg. Res., 53(4):349-56, 1992.

3626. Barratt, E.S., Faulk, D.M., Brandt, M.E., and Bryant, S.G., Effects of phenytoin on N100 augmenting/reducing and the late positive complex of the event-related potential: A topographic analysis, Neuropsychobiology, 15: 201-7, 1986.

3627. Barratt, E.S., Shappell, S.A., and Brandt, M.E., Effects of acute phenytoin on cortical event-related potentials, Soc. Neurosci. Abstr., 14(PT 2): 1105, 1988.

3628. Barratt, E.S., Kent, T., Bryant, S., Felthous, A., and Stanford, M., Phenytoin improves brain functions among impulsive aggressive prisoners, Soc. Neurosci. Abstr.,16(PT 1): 141, 1990.

3629. Barratt, E.S., Kent, T., and Stanford, M., The effects of phenytoin on event-related potentials among impulsive aggressive prisoners, Presented at the 3rd International Brain Research Organization World Congress of Neuroscience, Montreal, Canada, 342, ABS P53.10, 1991.

3630. Barratt, E.S. and Kent, T., The effects of phenytoin (PHT) on frontal and parietal event-related potentials(ERPs) among impulsive aggressive prisoners, Presented at the XVIIIth Collegium International Neuropsychopharmacolicum Congress, Nice, France, 1992.

3631. Barratt, E.S., Stanford, M.S., Felthous, A.R., and Kent, T.A., The effects of phenytoin on impulsive and premeditated aggression: a controlled study, J. Clin. Psychopharmacology, 17(5): 341-349, 1997.

3632. Barratt E.S., Orozco-Cabal, L.F., Mishalaine, J., and Moeller, F.G., The effects of phenytoin and sodium valproate on cortical ERP's: Implications for impulsivity, Soc. Neurosci. Abstr., 2003.

3633. Keele, N.B., Phenytoin inhibits isolation-induced aggression specifically in rats with low serotonin, Neuroreport, 12(6): 1107-1112, 2001.

3634. Voigt, J.P., Morgensterne, E., Comparative effects of carbamazepine, phenytoin, diazepam and clonazepam on inhibitory avoidance learning in mice, Psychopharmacology (Berlin), 108(1-2): 131-35, 1992.

3635. Declerck, A.C. and Wauquier, A., Influence of antiepileptic drugs on sleep patterns, Epilepsy Res. Suppl., 2: 153-163, 1991.

3636. Sammaritano, M. and Sherwin, A., Effect of anticonvulsants on sleep, Neurology, 54(1):S17-S24, 2000.

3637. McLean, M.J. and Blumenkopf, B., Anticonvulsants limit repetitive firing of action potentials induced by baclofen and forforskolin in cultured mammalian dorsal root ganglion neurons, Neurology, 37(S1): 236, 1987.

3638. Reichlin, S. and Mothon, S., Carbamezepine and phenytoin inhibit somatostatin release from dispersed cerebral cells in culture, Ann. Neurol., 29: 413-417, 1991.

3639. Sharif, R.N., Yashpal, K. and Henry, J.L., Phenytoin-induced anti-hyperalgesia but not antinociception in the rat tail-flick test, Soc. Neurosci. Abstr., 25(PT2):771.4, 1999.

3640. Backonja, M.M., Anticonvulsants (antineuropathics) for neuropathic pain syndromes, Clin. J. Pain, 16:S67-S72, 2000.

3641. Tsai, C.S., Smith, M.O., Robinson, T.J, Olubadewo, J.O., and Ochillo, R.F., Pharmacodynamic basis of the therapeutic use of phenytoin to manage alcohol withdrawal syndrome, Faseb J., 7(3):A255,1474, 1993.

3642. Vernillo, A.T. and Schwartz, N.B., Stimulation of collagen and glycosaminoglycan production by phenytoin 5,5-diphenylhydantoin in monolayer cultures of mesenchymal cells derived from embryonic chick sternae, Arch. Oral Biol., 31(12): 819-23, 1986.

3643. Vernillo, A.T. and Sschwartz, N.B., The effects of phenytoin (5,5-diphenylhydantoin) on human gingival fibroblasts in culture, J. Periodontol. Res., 22(4): 307-12, 1987.

3644. Dill, R.E., Davis, W.L., and Zimmermann, E.R., Quantitation of phagocytic cells in phenytoin-induced connective tissue proliferation in the rat, J.Periodontol., 59(3): 190-7, 1988.

3645. Narayanan, A.S., Meyers, D.F., and Page, R.C., Regulation of collagen production in fibroblasts cultured from normal and phenytoin-induced hyperplastic human gingiva, J. Periodont. Res., 23: 118-21, 1988.

3646. Modeer, T., Mendez, C., Dahllof, G., Anduren, I., and Andersson, G., Effect of phenytoin medication on the metabolism of epidermal growth factor receptor in cultured gingival fibroblasts, J. Periodont. Res., 25: 120-127, 1990.

3647. Modeer, T., Anduren, I., and Lerner, U.H., Enhanced prostaglandin biosynthesis in human gingival fibroblasts isolated from patients treated with phenytoin, J. Oral Pathol. Med., 21(3): 251-55, 1992.

3648. Modeer, T., Brunius, G., Iinuma, M., and Lerner, U.H., Phenytoin potentiates interleukin-1-induced prostaglandin biosynthesis in human gingival fibroblasts, Br. J. Pharmacol., 106(3): 574-578, 1992.

3649. Dill, R.E., Miller, E.K., Weil, T., Lesley, S., Farmer, G.R., and Iacopino, A.M., Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J. Periodontol., 64(3): 169-173, 1993.

3650. Cen, Y., Yu, B., and Ren, L., Experimental study of the effect of phenytoin on the healing of wounds, Chin. J. Reparative Reconstr. Surg., 8(1): 31-33, 1994.

3651. Genever, P.G., Cunliffe, W.J., and Wood, E.J., Influence of the extramolecular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models, Br. J. Dermatol., 133(2):231-5, 1995.

3652. Saito, K., Mori, S., Iwakura, M., and Sakamoto, S., Immunohistochemical localization of transforming growth factor , basic fribroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin, J. Periodont. Res., 31:545-555, 1996.

3653. Dill, R.E. and Iacopino, A.M., Myofibroblasts in phenytoin-induced hyperplastic connective tissue in the rat and in human gingival overgrowth, J. Periodontol., 68(4):375-380, 1997.

3654. Huang, J.S., Chen, J.K., Chen, C.P., Juan, G., Bhatnagar, R.S., and Liu, T.Z., Fibroblasts derived from tissue explants of dilantin-induced gingival hyperplasia and idiopathic gingival fibromatosis show distinct disparity in proliferative responsiveness to epidermal growth factor, Kaohsiung J. Med. Sci., 13(10):598-604, 1997.

3655. Iacopino, A.M., Doxey, D., Cutler, C.W., Nares, S., Stoever, K., Fojt, J., Gonzales, A., and Dill, R.E., Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia, J. Periodontol., 68(1):73-83, 1997.

3656. DaCosta, M.L., Regan, M.C., Al Sader, M., Leader, M., and Bouchier-Hayes D., Diphenyhydantoin sodium promotes early and marked angiogenesis and results in increased collagen deposition and tensile strength in healing wounds, Surgery, 123(3):287-293, 1998.

3657. Sasaki, T. and Maita, E., Increased bFGF level in the serum of patients with phenytoin-induced gingival overgrowth, J. Clin. Periodontol., 25:42-47, 1998.

3658. Das, S.J. and Olsen, I., Up-regulation of keratinocyte growth factor and receptor: a possible mechanisms of action of phenytoin in wound healing, Biochem. Biophys. Res. Commun., 282: 875-881, 2001.

3659. Vijayasingham, S.M., Dykes, P.J., and Marks, R., Phenytoin has little effect on in vitro models of wound healing, Br. J. Dermatol., 125: 136-39, 1991.

3660. Chen, Y., Yu, B.L., Ren L.S., Experimental studies of the effects on wound healing with topical phenytoin, Presented at the National Workshop of Clinical Use of Phenytoin, Chengdu, China, 1992.

3661. Soory, M. and Suchak, A., The effects of human mast-cell products and of phenytoin on androgen 5a-reductase expression in human gingival fibroblasts, Arch. Oral Biol., 46:847-855, 2001.

3662. Uzel M.I., Kantarci, A., Hong H.H., Uygur, C., Sheef, M., Firatli, E., and Trackman, P.C., Connective tissue growth factor in drug-induced gingival overgrowth, J. Periodontol., 72: 921-931, 2001.

3663. Modeer, T., Domeij, H., Anduren, I., Mustafa, M., and Brunius, G., Effect of phenytoin on the production of interleukin-6 and interleukin-8 in human gingival fibroblasts, J. Oral Pathol. Med., 29: 491-9, 2000.

3664. Modeer, T., Anduren, I., Bengtsson, A., and Andersson, G., Interleukin-1 and phenytoin reduce a1(I) procollagen mRNA expression in human gingival fibroblasts, J. Periodont. Res., 31: 563-569, 1996.

3665. Vernillo, A.T., Ramamurthy,N.S., Lee, H.M., and Rifkin, B.R., The effect of phenytoin on collagenase and gelatinase activities in UMR106-01 rat osteoblastic osteosarcoma cells, Matrix, 10: 27-32, 1990.

3666. Schirrmacher, K., Brummer, F., Dusing, R., and Bingmann, D., Dye and electric coupling between osteoblast-like cells in culture, Calcif. Tissue Int., 53(1): 53-60, 1993.

3667. Nakade, O., Baylink, D.J., and Lau, K.H., Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-derived bone cells in vitro, J. Dent. Res., 74(1): 331-337, 1995.

3668. Ohta, T., Wergedal, J.E., Gruber, H.E., Baylink, D.J., and William Lau, K.H., Low dose phenytoin is an osteogenic agent in the rat, Calcif. Tissue Int., 56(1):42-8, 1995.

3669. Ohta, T., Wergedal, J.E., Matsuyama, T., H.E., Baylink, D.J.,and William Lau, K.H., Phenytoin and fluoride act in concert to stimulate bone formation and to increase bone volume in adult male rats, Calcif. Tissue Int., 56: 390-397, 1995.

3670. Karsten, J. and Hellsing, E., Effect of phenytoin on periodontal tissues exposed to orthodontic force - an experimental study in rats Br. J. Orthod.,24(3):209-215, 1997.

3671. Ikedo, D., Ohishi, K., Yamauchi, N., Kataoka, M., Kido, J., and Nagata, T., Stimulatory effects of phenytoin on osteoblastic differentiation of fetal rat calvaria cells in culture, Bone, 25(6): 653-660, 1999.

3672. Koyama, H., Nakade, O., Saitoh, T., Takuma, T., and Kaku, T., Evidence for the involvement of bone morphogenetic protein-2 phenytoin-stimulated osteocalcin secretion in human bone cells, Arch. Oral Biol., 45(8): 647-55, 2000.

3673. Lau, K.H., Nakade, O., Barr, B., Taylor, A.K., Houchin, K., and Baylink, D.J., Phenytoin increases markers of osteogenesis for the human species in vitro and in vivo, J. Clin. Endocrinol. Metab., 80(8):2347-53, 1995.

3674. Pedrera, J.D., Canal, M.L., Carvajal, J., Postigo, S., Villa, L.F., Hernandez, E.R., and Rico, H., Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy, Eur. J. Clin. Invest., 30(10):895-9, 2000.

3675. Onodera, K., Takahashi, A., Mayanagi, H., Wakabayashi, H., Kamei, J., and Shinoda, H., Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats, Calcif. Tissue Int., 69: 109-116, 2001.

3676. Talas, G., Adams, T.S.T., Eastwood, M., Rubio, G., and Brown, R.A., Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels, Int. J. Biochem. Cell Biol., 29(1):261-270, 1997.

3677. Cunnane, S.C., Kent, E.T., McAdoo, K.R., Caldwell, D., Lin, A.N., and Carter, D.M., Abnormalities of plasma and erythrocyte essential fatty acid composition in epidermolysis bullosa: Influence of treatment with diphenylhydantoin, J. Invest. Dermatol., 89: 395-9, 1987.

3678. Fine, J.D. and Johnson, L., Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa, Arch. Dermatol., 124: 1402-6, 1988.

3679. Pappu-Katikaneni, L.D. and Wiest, D.B., Phenytoin (PHT) dosing requirements and blister fluid concentrations (BFC) in a junctional epidermolysis bullosa (JEB) patient, Pediatr. Res., 23(4):262A, 1988.

3680. Lin, A.N., Stern, R.S., Caldwell-Brown, D., and Carter, D.M., Phenytoin for recessive dystrophic epidermolysis bullosa, Clin. Res., 37(2): 625A, 1989.

3681. Caldwell-Brown, D., Stern, R.S., Lin, A.N., and Carter, D.M., Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa, N. Engl. J. Med., 327(3): 163-167, 1992.

3682. Masgrau-Peya, E., Lacour, M., and Salomon, D., Topical phenytoin accelerates healing in epidermolysis bullosa simplex, Dermatology, 190(3):254, 1995.

3683. Fine, J.D., Epidermolysis bullosa, clinical aspects, pathology, and recent advances in research, Int. J. Dermatol., 25: 143-57, 1986.

3684. Nawaz, A., Matta, H., Jacobsz, A., and Al-Salem, A., Congenital pyloric atresia and junctional epidermolysis bullosa: a report of two cases, Pediatr. Surg. Int., 16(3):206-8, 2000.

3685. Fine, J.D. and Johnson, L., Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa (JEB), J. Clin. Pharmacol., 27(9): 723, 1987.

3686. Pearson, R.W. and Paller, A.S., Dermolytic (dystrophic) epidermolysis bullosa inverse, Arch. Dermatol., 124: 544-7, 1988.

3687. Kern, I.B., Eisenberg, M., and Willis, S., Management of oesophageal stenosis in epidermolysis bullosa dystrophica, Arch. Dis. Child., 64: 551-6, 1989.

3688. Popov, N., Contemporary problems in epidermolysis bullosa in view of four cases under observation, Pediatriya (Sofia), 27(4): 64-72, 1988.

3689. Talas, G., Adams, T.S.T., Eastwood, M., Rubio, G., and Brown, R.A., Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels, Int. J. Biochem. Cell Biol., 29(1):261-270, 1997.

3690. Sechi, G.P., Melis, F., Caria, M.A., Tanca, S., and Rosati, G., Ketamine may interact with phenytoin at a pharmacokinetic and a pharmacodynamic level, Adv. Epileptol., 17: 185-88, 1989.

3691. Lordo, C.S., Troude, E., and Del Maestro, R.F., The effect of diphenyhydantoin and dexamethasone on C6 astrocytoma radiosensitivity, Can. J. Neurol. Sci.,13(3): 280, 1986.

3692. Dyce, M., Sharif, S.F., and Whalen, G.F., Search for anti-metastatic therapy: effects of phenytoin on B16 melanoma metastasis, J. Surg. Oncol., 49:107-12, 1992.

3693. Tittle, T.V. and Schaumann, B.A., Effect of antiepileptic drugs on growth of murine lymphoid tumor cells in single-cell culture, Epilepsia, 33(4):729-735, 1992.

3694. Tittle, T.V., Schaumann, B.A., Rainey, J.E., and Taylor, K., Segregation of the growth slowing effects of valproic acid from phenytoin and carbamezepine on lymphoid tumor cells, Life Sci., 50: 79-83, 1992.

3695. Ganapathi, R., Hercbergs, A., Grabowski, D., and Ford, J., Selective enhancement of vincristine cytotoxicity in multi-drug resistant tumor cells by dilantin (phenytoin), Cancer Res., 53(14):3262-5, 1993.

3696. Hirai, A., Ishizuka, J., Hirai, M., Sato, K., Cooper, C.W., Townsend, C.M., Thompson, J.C., Antiproliferative effect of calcium channel blockers on human colon cancer cell lines, Personal Communication, 1-22, 1994.

3697. Sato, K., Ishizuka, J., Cooper, C.W., Chung, D.H., Uchida, T., Rajaraman, S., Townsend, C.M., Thompson, J.C., and Tsuchiya, Y., Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells, Pancreas, 9(2): 193-202, 1994.

3698. Tonn, J.C., Haugland, H.K., Saraste, J., Roosen, K., and Laerum, O.D., Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines J. Neurosurg., 82(6):1035-43, 1995.

3699. Kawamura, K.I., Grabowski, D., Weizer, K., Bukowski, R., and Ganapathi, R., Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumor cells, B. J. Cancer, 73:183-88, 1996.

3700. Borovansky, J., Blasko, M., Siracky, J., Schothorst, A.A., Smit, N.P.M., and Pavel, S., Cytotoxic interactions of Zn 2+ in vitro: melanoma cells are more susceptible than melanocytes, Melanoma Res., 7:449-453, 1997.

3701. Stander, M., Dichgans, J., and Weller M., Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells, J. Neuro-Oncol., 37:191-198, 1998.

3702. Abdul, M., and Hoosein, N., Inhibition by antoconvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells, Anticancer Res., 21: 2045-2048, 2001.

3703. Slesinger, P.A. and Singer, H.S., Effects of anticonvulsants on cell growth and enzymatic and receptor binding activity in a neuroblastoma X Glioma hybrid cell culture, Epilepsia, 28(3): 214-21, 1987.

3704. Lobert, S., Ingram, J.W., and Correia, J.J., Additivity of dilantin and vinblastone inhibitory effects on microtubule assay, Cancer Res., 59:4816-4822, 1999.

3705. Sato, K., Cooper, C.W., Cooper, K.M., Chung, D.H., Ishizuka, J., Townsend, C.M., and Thompson, J.C., Inhibitory effect of phenytoin and verapamil and growth of pancreatic cancer cells in vitro and in vivo, Presented to, American Gastroenterological Association/American Association for the study of liver diseases, May 10-13, 1992, San Francisco, CA, 1992.

3706. Kryzhanovskii, G.N., Atadzhanov, M.A., and Kucheryanu, V.G., Effect of phenytoin sodium on an experimental parkinsonian syndrome, Biull. Eksp. Biol. Med. (Moscow), 110(9): 1169-72, 1990.

3707. Mackinney, A.A., Knobeloch, L., and Norback, D., The effect of diphenylhydantoin and cortisol on the cell cycle, Proc. Soc. Exp. Biol. Med., 188: 173-176, 1988.

3708. Andrade-Mena, C.E., Sardo-Olmedo, J.A., and Ramirez-Lizardo, E.J., Effects of phenytoin administration on murine immune function, J. Neuroimmunol., 50(1): 3-7, 1994.

3709. Okada, K., Sugiura, T., Kuroda, E., Tsuji, S., and Yamashita U., Phenytoin promotes the Th2 type immune response in mice, Clin. Exp. Immunol., 124: 406-413, 2001.

3710. Okamoto, Y., Shimizu, K., Miyao, Y., Tamura, K., Yamada, M., Matsui, Y., Tsuda, N., and Mogami, H., Effects of phenytoin on immunity, Igaku. No. Ayumi., 137(12):1025-6, 1986.

3711. Ricevuti, G., Mazzone, A., and Pasotti, In vitro effects of phenytoin on neutrophil functions, Med. Sci. Res., 16(14): 741-3, 1988.

3712. Petrasch, S, Bechtold, D., Zou, P., Wacker, H.H., and Brittinger, G, Diphenylhydantoin-induced increase of antigen-binding cells in the ymphatic tissue, Aids-Forschung, 6: 339-41, 1988.

3713. Cloyd, M.W., Lynn, W.S., Ramsey, K., and Baron, S., Inhibition of human immunodeficiency virus (HIV-1) infection by diphenylhydantoin (dilantin) implicates role of cellular calcium in virus life cycle, Virology, 173: 581-590, 1989.

3714. Petrasch, S., Wacker, H.H., Zou, P., Bechtold, D., and Brittinger, G., Enhancement in number and function of antigen-presenting cells in the lymphatic tissue of rats after in vivo administration of diphenylhydantoin (DPH), Clin. Exp. Immunol, 78: 133-37, 1989.

3715. Lehr, H.A., Zimmer, J.P., Hubner, C., Ballmann, M., Hachmann, W., Vogel, W., Baisch, H., Hartter, P., Albani, M., and Kohlschutter, A., Decreased binding of HIV-1 and vasoactive intestinal peptide following plasma membrane fluidization of CD4+ cells by phenytoin, Virology, 179(2): 609-17, 1990.

3716. Shorvon, S.D., Is there a therapeutic range for phenytoin? in: Fifty Years of Phenytoin, International Congress and Symposium Series Number 120, Dam, M. & Richens, A., eds., Royal Society of Medicine Services, London, 13-8,1987.

3717. Umstead, G.S., and Neumann, K.H., Correlation of free phenytoin to serum albumin in cancer patients, DICP, 24: 923-926, 1990.

3718. Rambeck, B., Schnabel, R., May, T., Jurgens, U., and Villagran, R., Postmortem concentrations of phenytoin in different regions of the brain and in the serum: analysis of autoptic specimens from 24 epileptic patients, Ther. Drug Monit., 14: 27-35, 1992.

3719. Kaplan, B., and Krumlovsky, F.A., Phenytoin in end-stage renal disease, Int. J. Artif. Organs, 15(2): 69-70, 1992.

3720. Hayes, G., and Kootsikas, M.E., Reassessing the lower end of the phenytoin therapeutic range: a review of the literature, Ann. Pharmacother, 27(11):1389-92, 1993.

3721. Scheyer, R.D., During, M.J., Hochholzer, J.M., Spencer, D.D., Cramer, J.A., and Mattson, R.H., Phenytoin concentrations in the human brain: an in vivo microdialysis study, Epilepsy Res., 18(3):227-32, 1994.

3722. Wilder, B.J., Use of parenteral antiepileptic drugs and the role of fosphenytoin, Neurology, 46(SUPP1):S1-2, 1996.

3723. Browne, T.R., Kugler, A.R., and Eldon, M.A., Pharmacology and pharmacokinetics of fosphenytoin, Neurology, 46(SUPP1):S3-7, 1996.

3724. Luer, M.S., Fosphenytoin, Neurol. Res., 20:178-182, 1998.

3725. Ramsay, R.E., Wilder, B.J., Uthman, B.M., Garnett, W.R., Pellock, J.M., Barkley, G.L., Leppik, .I.E., and Knapp, L.E., Intramuscular fosphenytoin (cerebyx R) in patients requiring a loading dose of phenytoin, Epilepsy Res., 28:181-187, 1997.

3726. Dasgupta, A., Datta, P., Redlich, G., and Limmany, A., Analytical performance of a new chemiluminescent phenytoin (ACS:180) assay, Ther. Drug Monit.,19:191-194, 1997.

3727. Eadie, M.J., Therapeutic drug-monitoring - antiepileptic drugs, Br. J. Pharmacol., 46:185-193, 1998.

3728. Frame, B., and Beal, S.L., Non-steady state population kinetics of intravenous phenytoin, Ther. Drug Monit., 20:408-416, 1998.

3729. Kodama, H., Kodama, Y., Shinozawa, S., Kanemaru, R., Todaka, K., and Mitsuyama, Y., Serum protein binding kinetics of phenytoin in monotherapy patients, J. Clin. Pharm. Ther., 23:361-365, 1998.

3730. Takeoka, M., Krishnamoorthy, K.S., Soman, T.B., and Caviness, V.S., Fosphenytoin in infants, J. Child Neurol., 13(11):537-540, 1998.

3731. Dasgupta, A., and Havlik, D., Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin, Ther. Drug Monit., 20:658-662, 1998.

3732. Holliday, S.M., Benfield, P., and Plosker, G.L., Fosphenytoin. Pharmacoeconomic implications of therapy, Pharmacoeconomics.,14(6):685-690, 1998.

3733. Roberts, W.L., De, B.K., Coleman, J.P., and Annesley, T.M., Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin, Clin. Chem., 45(6):829-837, 1999.

3734. Armstrong, E.P., Sauer, K.A., and Downey, M.J., Phenytoin and fosphenytoin: a model of cost and clinical outcomes, Pharmacotherapy, 19(7):844-853, 1999.

3735. Wilder, B.J., Leppik, I., Hietpas, T., Cloyd, J.C., and Cook, J., Clinical implications of the effect of food on the bioavailability of dilantin kapseals versus mylan extended phenytoin sodium capsules, Neurology, 54(S3):A193, 2000.

3736. Romanelli, F., Jennings, H.R., Nath, A., Ryan, M., and Berger, J., Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals, Neurology, 54(7):1404-1407, 2000.

3737. Meek, P.D., Davis, S.N., Collins, D.M., Gidal, B.E., Rutecki, P.A., Burstein, A.H., Fischer, J.H., Leppik, I.E., and Ramsay, R.E., Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process, Arch. Intern. Med., 159(22):2639-44, 1999.

3738. Bachmann, K., and Belloto, R.J. Jr., Differential kinetics of phenytoin in elderly patients, Drugs Aging, 15(3):235-250, 1999.

3739. Kodama, H., Kodama, Y., Shinozawa, S., Kanemaru, R., Itokazu, N., and Sugimoto, T., In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy, Int. J. Clin. Pharmacol. Ther., 38(1):25-29, 2000.

3740. Pryor, F.M., Gidal, B., Ramsay, E., DeToledo, J., and Morgan, R.O., Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses, Epilepsia, 42(2):245-250, 2001.

3741. Burkhardt, R.T., Leppik, .I.E, Blesi, K., Deblieck, S., Gapany, S.R., Hietpas, T.J., and Cloyd, J.C., Apparent increased seizures and lowered phenytoin (PHT) levels in persons with epilepsy switched from brand to generic extended PHT sodium capsules, Epilepsia, 41(S7):231, 2000.

3742. Musib, L.C., Cloyd, J.C., Birnbaum, A.K., Hietpas, T.J., Leppik, I.K., Browne, T.R., Holloway, S.F., Holden, G.S., and Rarick, J.O., Preliminary report on phenytoin pharmacokinetics in the elderly using an intravenous stable-labeled isotope, Epilepsia, 41(S7):231, 2000.

3743. DeToledo, J.C., and Ramsay, R.E., Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs, Drug Safety, 22(6):459-66, 2000.

3744. Spruill, W.J., Wade, W.E., Cobb, H.H., and Akbari, S., Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of phenytoin in an outpatient neurology practice, Pharmacotherapy, 345(7):538-541, 2001.

3745. Wilder, B.J., Leppik, I., Hietpas, T.J., Cloyd, J.C., Randinitis, E.J. and Cook, J., Effect of food on absorption of dilantin kapseals and mylan extended phenytoin sodium capsules, Neurology, 57(4):582-589, 2001.

3746. Cook, J., Randinitis, E., and Wilder, B.J., Effect of food on the bioavailability of 100-mg dilantin kapseals, Neurology, 57(4):698-700, 2001.

3747. Huang, M-Y., Eddy, T., and Liu, S., Single-dose fasting bioequivalence study for mylan 100 mg extended phenytoin sodium capsules, Epilepsia, 42(S7):90, 2001.

3748. Kriel, R.L., Cifuentes, R.F., Fosphenytoin in infants of extremely low birth weight, Pediatr. Neurol., 24(3):219-221, 2001.

3749. Potschka, H., and Loscher, W., Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain, Neuroreport, 12(11):2387-89, 2001.

3750. Kodama, H., Kodama, Y., Shinozawa, S., Kanemaru, R., Todaka, K., and Mitsuyama, Y., Effect of temperature on binding characteristics of phenytoin to serum proteins in monotherapy adult patients with epilepsy, Am. J. Ther., 7:11-15, 2000.

3751. Kodama, H., Kodama, Y., Shinozawa, S., Ranemaru, R., Todaka, K., and Mitsuyama, Y., No gender effect on binding characteristics of phenytoin to serum proteins in monotherapy for adult patients with epilepsy, Am. J. Ther., 7:285-289, 2000.

3752. Kitchen, D., and Smith, D., Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding, Seizure, 10:265-268, 2001.

3753. Monaghan, M.S., Marx, M.A., Olsen, K.M., Turner, P.D., and Bergman, K.L., Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation, Ther. Drug Monit., 23:263-267, 2001.

3754. Iida, Y., Nishi, S., and Asada, A., Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics, Ther. Drug Monit.T, 23:192-197, 2001.

3755. Kodama, H., Kodama, Y., Tokazu, N., Shinozawa, S., Kanemaru, R., and Sugimoto, T., Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy, J. Clin. Pharm.Ther., 26:175-179, 2001.

3756. Sonnenfeld, G. and Nerland, D.E., Measurement of effect of interferon on metabolism of diphenylhydantoin, Methods Enzymol, 119: 715-8, 1986.

3757. MacKinney, A.A. and Knobeloch, L., Diphenylhydantoin inhibits cortisol-induced lysis of thymocytes, Proc. Soc. Exp. Biol. Med., 182: 474-7, 1986.

3758. Cusack, B.J., Tesnohlidek, D.A., Loseke, V.L., Vestal, R.E., Brenner, D.E., and Olson, R.D., Effect of phenytoin on doxorubican and doxorubicinol pharmacokinetics in the rabbit, Clin. Res, 36:362A, 1988.

3759. Thompson, K.W. and Wasterlain, C.G., Dextromethorphan and its combination with phenytoin facilitate kindling, Neurology, 43(5): 992-994, 1993.

3760. Nicolas, J.M., Collart, P., Gerin, B., Mather, G., Trager, W., Levy, R., and Roba, J., In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent, Drug Metab. Dispos., 27(2):250-254, 1999.

3761. Schmider, J., Greenblatt, D.J., Von Moltke, L.L., Karsov, D., and Shader, RI, Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation, Br. J. Clin. Pharmacol., 44:495-498, 1997.

3762. Della Paschoa, O.E., Voskuyl, R.A., and Danhof, M., Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate, Br. J. Pharmacol, 125:1610-1616, 1998.

3763. Mizukami, Y., Yamada, S., Kokudo, N., Takashima, M., and Yokoyama, T., Dietary iron reduces the anti-convulsion activity of phenytoin in electroconvulsion via inhibition of brain penetration, Brain Res.,, 915:112-117, 2001.

3764. Simon, L., Kariya, N., Pelle-Lancien, E., and Mazoit, J.X., Bupivacaine-induced QRS prolongation is enhanced by lidocaine and by phenytoin in rabbit hearts, Anesth. Analg., 94:203-7, 2002.

3765. Matar, K.M., Nicholls, P.J., Tekle, A., Bawazir, S.A., and Al-Hassan, M.I., Effect of vigabatrin and gabapentin on phenytoin pharmacokinetics in the dog, Eur. J. Drug Metab. Pharmacokinet., 25(3/4):189-193, 2000.

3766. Tripathi, M., Sundaram, R., Rafiq, M., Venkataranganna, M.V., Gopumadhavan, S., and Mitra, S.K., Pharmacokinetic interactions of mentat with carbamazepine and phenytoin, Eur. J. Drug Metab. Pharmacokinet., 25(3/4):223-226, 2000.

3767. Chen, L.C., Cjou, M.H., Lin, M.F., and Yang, L.L., Effects of paeoniae radix, a traditional Chinese medicine on the pharmacokinetics of phenytoin, J. Clin. Pharm. Ther, 26:271-278, 2001.

Advisory